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Abstract
Phenylalanine (Phe), an essential aromatic amino acid, serves as a
precursor for protein synthesis and a variety of secondary metabolites in plants.
Two pathways are known for Phe biosynthesis. In the first, prephenate
dehydratases

(PDTs)

convert

prephenate

to

phenylpyruvate,

which

is

transaminated to Phe. In the second, prephenate is transaminated to arogenate,
which is converted to Phe by arogenate dehydratases (ADTs). ADTs and PDTs
are structurally very similar, as are their substrates. Six ADTs (ADT1-ADT6) have
been identified in Arabidopsis thaliana. ADT1 and ADT2 can recognize both
prephenate and arogenate as substrates whereas ADT3 – ADT6 are solely
arogenate-accepting. Twenty ADT domain-swapping chimeras were generated
through overlap extension PCR and were tested for PDT function in a pha2
complementation assay. Through targeted mutagenesis it was identified that a
Phe341Leu substitution in ADT5 was sufficient to introduce PDT function to this
previously solely-arogenate accepting ADT. This research represents the first
identification of any amino acid that discriminates an arogenate-only ADT from
an ADT that is able to accept prephenate
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1 Introduction
The research presented in this thesis is concerned with the final step of
the phenylalanine (Phe) biosynthesis pathway in Arabidopsis thaliana. This
step is catalyzed by arogenate dehydratases (ADTs). A family of six ADTs
(ADT1-ADT6) have been identified in Arabidopsis.

1.1 The importance of phenylalanine
Phe is an aromatic amino acid that is synthesized through the
shikimate pathway in plants, bacteria and fungi (Herrmann and Weaver 1999).
Phe is required for protein synthesis in all organisms, and therefore is an
important dietary component for organisms that cannot synthesize the amino
acid themselves, such as humans. In the United States alone, approximately
13,000 tons of Phe is artificially synthesized annually for use as a dietary
supplement. This is valued at 198 million USD (Demain and Fang 2000).
In plants, Phe is also a precursor to a diverse family of organic
compounds. These compounds, such as flavonoids, alkaloids, lignin and
suberin have a wide variety of important functions within the plant.
Flavonoids are aromatic molecules that are created when Phe is
converted to 4-coumaroyl-CoA (Falcone Ferreyra et al. 2012). These
molecules represent the major red, blue and purple pigments in plants. These
pigments recruit pollinators and seed dispersers (Winkel-Shirley 2001), which
allow plants to improve their reproductive success. In addition, flavonoid
pigments make flowering plants aesthetically pleasing and aesthetics such as
these drive the success of the fast-growing flower industry. In 2012, flower
and flower-related item sales were responsible for 27.8 billion dollars of
revenue in the United States alone (U.S. Bureau of Economic Analysis, July
31, 2013).
Alkaloids are a class of nitrogen-containing organic compounds that
are derived from Phe and tyrosine (Tyr; Facchini 2001). These molecules are
key mediators of the plant’s resistance towards pests. For example, loline
alkaloids, which are insecticidal compounds produced in grasses that are
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infected with endophytic fungi, increase resistance of the infected grasses to
aphid predation (Wilkinson et al. 2000).
Lignin and suberin are Phe-derived biopolymers. Lignin is a broad term
for a large group of complex cross-linking polymers of aromatic alcohols. This
cross-linking framework is found in plant secondary cell walls and confers
rigidity to the cell and stability to the plant as a whole (Vanholme et al. 2010).
Lignin is also quite hydrophobic, which makes it very important for water
conduction in vascular plants (Vogt 2010). Lignin crosslinking in the
secondary plant cell wall acts as an obstacle for water absorption into the cell,
and therefore lignin is a crucial component of cells involved in water transport,
such as xylem tracheids (Peter and Neale 2004). In fact, lignin is one of the
most abundant biopolymers on earth. Between 20 and 30% of the total carbon
that is fixed through photosynthesis is channeled through the Phe
biosynthesis pathway to the production of lignin, although this number differs
greatly depending on whether the plant is woody or herbaceous (Bonawitz
and Chapple 2010). Lignin has been a major focus of the biofuel industry due
to its role in the inhibition of microbial fermentation of the plant cell wall. This
inhibition decreases the efficiency of the energy conversion process in biofuel
production, resulting in significant revenue losses (Frei 2013).
Suberin is a cell wall biopolymer that is made up of both polyphenolic
and polyaliphatic domains (Bernards 2002). Similar to lignin, suberin functions
as a physical barrier to water movement within the plant. However, suberin
also plays a significant role in the wound healing process of plants. Wounded
plants focus their metabolic energy on the formation of this biopolymer, which
can seal off the wound and therefore prevent infection (Yang and Bernards
2007). For example, Soybean plants with increased suberin levels display
partial resistance to Phytophthora sojae, a soil-born pathogen which causes
root rot (Thomas et al. 2007). Root rot is responsible for millions of dollars of
potential Soybean revenue losses every year (Kaufmann and Gerdemann
1958).
Phe is produced in plants and microorganisms but not humans.
Therefore, enzymes in the Phe biosynthesis pathway can serve as drug
targets against microbial pathogens (Husain et al. 2001), or herbicides against
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invading plants (Tohge et al. 2013). In plants, the shikimate pathway has been
a target for herbicidal inhibition in the past (Tohge et al. 2013).

1.2 Phenylalanine biosynthesis
Phe biosynthesis begins with the shikimate pathway in plants, fungi,
and bacteria. The shikimate pathway is comprised of seven enzymatic
reactions which lead to the production of chorismate (Herrmann 1995).
Chorismate is the last common precursor of the three aromatic amino acids
tryptophan (Trp), tyrosine (Tyr) and Phe. In Phe biosynthesis, chorismate is
converted to prephenate by chorismate mutase (CM) (Herrmann and Weaver
1999; Tzin and Galili 2010). Two steps are then necessary to convert
prephenate

to

Phe:

a

decarboxylation/dehydration

step

and

an

aminotransferase step.
The order of these two steps, as well as the enzymes that catalyze
them, differ and therefore Phe biosynthesis can be divided into two pathways.
These pathways are called the prephenate pathway and the arogenate
pathway (Figure 1).
In the prephenate pathway, prephenate is converted to phenylpyruvate
via a decarboxylation/dehydration reaction. This reaction is catalyzed by a
prephenate

dehydratase

(PDT;

EC4.2.1.51).

Phenylpyruvate

is

then

converted to Phe by a phenylpyruvate aminotransferase (Cotton and Gibson
1965; Fazel et al. 1980; Bentley 1990). In the arogenate pathway, prephenate
is first transaminated to arogenate and arogenate is then converted to Phe in
a decarboxylation/dehydration reaction that is catalyzed by an arogenate
dehydratase (ADT; EC4.2.1.911). PDTs and ADTs both catalyze a
decarboxylation/dehydration reaction, and recognize substrates (prephenate
and arogenate, respectfully) that differ by only a single amino group (Figure
1).
Microorganisms predominantly synthesize Phe via the prephenate
pathway (Im and Pittard 1971). Plants, however, predominantly synthesize
Phe
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Figure 1. The last two steps of Phenylalanine biosynthesis.
Chorismate, the end-product of the shikimate pathway, is converted to
prephenate.

In

the

prephenate

pathway,

prephenate

is

decarboxylated/dehydrated by a PDT to phenylpyruvate. Phenylpyruvate is
then converted to phenylalanine by a PPAT. In the arogenate pathway,
prephenate is first converted to arogenate by a PAT, and is then converted via
a decarboxylation/dehydration reaction to phenylalanine by an ADT.
PDT: prephenate dehydratase; PPAT: phenylpyruvate aminotransferase;
PAT: prephenate aminotransferase; ADT: arogenate dehydratase. Modified
from Bentley 1990.
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via the arogenate pathway (Byng et al. 1981), with only one exception identified
in the literature (Yoo et al. 2013) in which an aminotransferase was identified in
Arabidopsis that could convert phenylpyruvate to phenylalanine. In addition,
some microorganisms can use both the arogenate and the prephenate pathways
to synthesize Phe (Zhao et al. 1992). These organisms employ enzymes called
cyclohexadienyl dehydratases (CDTs), which can accept both arogenate and
prephenate as substrates. However, CDTs are quite different from ADTs and
PDTs at the sequence level.
Some microorganisms employ a PDT-CM fusion protein, known as a Pprotein (Zhang et al. 1998). These proteins can both convert chorismate to
prephenate and convert prephenate to phenylpyruvate.

1.3 Sequence comparison of PDTs and ADTs
While searching for putative PDT-domain encoding proteins in Arabidopsis
thaliana, Cho et al. (2007) and Ehlting et al. (2005) identified a family of six PDTlike enzymes. Through biochemical and yeast complementation analyses, these
enzymes were shown to produce Phe predominantly via the arogenate pathway
(Cho et al. 2007; Bross et al. 2011), and therefore were named ADT1-ADT6
(ADT1, At1g11790; ADT2, At3g07630; ADT3, At2g27820; ADT4, At3g44720;
ADT5, At5g22630; and ADT6, At1g08250). ADT1 and ADT2 contain introns,
whereas ADT3-ADT6 do not.
Phylogenetic analysis suggests that the bacterial and plant enzymes are
evolutionarily distinct (Figure 2). The plant sequences used in this tree include
the Arabidopsis ADTs listed above, as well as three Petunia hybrida ADTs
(PhADT1: ACY79502.1; PhADT2: ACY79503.1; PhADT3: ACY79504.1) and five
Oriza sativa ADTs (OsADT1: CBC52502.1; OsADT2: CBC52495.1; OsADT3:
CBC52493.1; OsADT4: CBC87919.1; OsADT5: CAW84916.1). The bacterial
sequences are listed in Table 1. When comparing the bacterial PDTs, the
sequences branch into two groups: one containing Gram-positive bacteria and
one containing Gram-negative bacteria, with the exception of Deinococcus
radiodurans and Magnetococcus marinus, which are Gram-positive but cluster

	
  

	
   7	
  

Figure 2. Phylogenetic tree of plant ADTs and bacterial PDTs.
Rooted phylogenetic tree generated with DNAMAN using a bootstrap of 1000.
Branch point numbers represent the boot-strapping values and horizontal scale
indicates sequence divergence. All sequences that are included in this tree
contain both a catalytic domain and an ACT regulatory domain, the transit
peptides of the plant sequences have been removed. Dashed lines separate the
clustering of the plant sequences into subgroups and bacterial sequences into
Gram-positive and Gram-negative groups (with the exception of Deinococcus
radiodurans and Magnetococcus marinus, which are Gram-positive but cluster
with the Gram-negative ADTs). The plant ADT sequences are highlighted in
green and the enterobacterial PDT sequences are highlighted in yellow. A CDT
sequence from Pseudomonas aeruginosa is included as a representative of
these enzymes.
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Table 1. List of bacterial PDT sequences used in PDT sequence alignment.

Amino Acids

Bacteria Species

Accession Number

Agrobacterium tumefaciens

EGL66829.1

6

Negative

Bacillus anthracis

WP_000621720.1

2

Positive

Bacillus subtilis

AEP91783.1

-

Positive

Bradyrhizobium japonicum

WP_024340564.1

4

Negative

Brucella suis

AIB30268.1

7

Negative

Chlorobium tepidum

NP_662549.1

4

Negative

Deinococcus radiodurans

WP_010887790.1

-

Positive

Enterococcus faecalis

WP_024797082.1

-

Positive

Erwinia herbicola

CAH09395.1

-

Negative

Escherichia coli

WP_001324213.1

-

Negative

Haemophilus influenzae

AHL61944.1

-

Negative

Lactococcus lactis

WP_011835672.1

1

Positive

Listeria innocua

WP_003767020.1

1

Positive

	
  

Removeda

Gram Strain
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Table 1. (continued). List of bacterial PDT sequences used in PDT sequence alignment.

Bacteria Species

Accession Number

Amino Acids

Gram Stain

Removeda

a

Listeria monocytogenes

AHN32779.1

1

Positive

Magnetococcus marinus

ABK44389.1

1

Positive

Magnetospirillum magnetotacticum

WP_018726497.1

9

Negative

Mesorhizobium loti

WP_019863035.1

6

Negative

Pseudomonas aeruginosa

WP_024914965.1

1

Negative

Pseudomonas stutzeri

AHL75120.1

1

Negative

Rhizobium meliloti

NP_384330

6

Negative

Rhodopseudomonas palustris

WP_013501421.1

1

Negative

Salmonella typhimurius

AGK68175.1

1

Negative

Staphylococcus aureus

AIA28436.1

1

Positive

Streptococcus pneumoniae

KDE93426.1

1

Positive

Thermoanaerobacter tengcongensis

NP_622663

7

Negative

Vibrio cholerae

NP_230354

1

Negative

Number of amino acids removed from the N-terminus.
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with the Gram-negative ADTs. In general, Gram-positive bacteria express a
monofunctional enzyme while Gram-negative bacteria express a bifunctional PProtein.
There is a high level of sequence diversity among the bacterial PDTs. For
example, the bacterial sequences used in the phylogenetic alignment in Figure 2
have an overall identity of only 45.8%. The PDTs from Chlorobidium tepidum and
Staphylococcus aureus, which will be discussed further (section 1.6; Boavida et
al. 2005) have a sequence identity of only 27.3% even though they are
functionally very similar (Tan et al. 2008). Due to this diversity it is currently
impossible to identify the exact amino acids that can distinguish between an ADT
and a PDT based on the protein sequences alone.
When aligned with ADT sequences from several other plant species, the
six Arabidopsis ADTs branch into three subgroups (Figure 2). ADT1 and ADT2
branch into Sub Groups I and II, respectively, and ADT3-ADT6 group together in
Sub Group III. Of the Arabidopsis ADTs, ADT4 and ADT5 show the highest
degree of sequence identity (82% identity).

1.4 Substrate specificity
1.4.1 Substrate specificity of ADTs in vitro
In vitro biochemical analysis of the six Arabidopsis ADTs (Cho et al. 2007)
indicates that all six enzymes preferentially accept arogenate as a substrate
(Table 2). However, when tested for the ability to accept prephenate as a
substrate, three of these enzymes (ADT1, ADT2 and ADT6) also displayed a low
level of PDT function. The catalytic efficiency values (kcat/Km) of ADT1, ADT2 and
ADT6 were 28, 32, and 98 times greater for arogenate recognition than
prephenate, respectively. This dual substrate recognition can be found in ADT
enzyme families in other plant species as well. For example, enzymes with the
capacity to accept both arogenate and prephenate have also been identified in
Petunia hybrida, in which two out of a family of three ADTs are also able to
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Table 2. Ability of ADTs to use prephenate versus arogenate as a substrate.

Substratea

Arogenate

a

Vmax

kcat/Km

Vmax

kcat/Km

Complement

ADT

[pkat µg-1]

[M-1 S-1]

[pkat µg-1]

[M-1 S-1]

pha2b

ADT1

31.00

1050

0.28

38

Yes

ADT2

60.60

7650

1.6

240

Yes

ADT3

5.17

1140

-

-

No

ADT4

52.32

490

-

-

No

ADT5

11.26

620

-

-

No

ADT6

42.61

1560

0.4

16

No

: data from Cho et al., 2007.

b

Ability to

Prephenate

: data from Bross et al., 2011.
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accept prephenate as a substrate (Maeda et al. 2010). The catalytic efficiency
values for arogenate recognition of these enzymes were approximately 100 and
200 times greater than those for prephenate recognition. Before the results
presented in this study, the specific amino acid sequence(s) that can distinguish
an arogenate-only ADT from an arogenate- and prephenate-accepting ADT had
not been identified.
1.4.2 Substrate specificity of ADTs in vivo
ADT1-ADT6 were subsequently tested for their ability to recognize
prephenate as a substrate in a yeast complementation assay in vivo (Bross et al.
2011). Saccharomyces cerevisiae, also called “bakers yeast”, utilizes only the
prephenate pathway to produce Phe. The unicellular eukaryote contains one
PDT gene, PHA2, which encodes for the only PDT protein in this organism.
When PHA2 is knocked out, the yeast cannot survive without either an
exogenous supply of Phe or a transformed gene that expresses a protein with
PDT activity.
The six ADT enzymes were expressed in a pha2 knockout S. cerevisiae
strain. ADT1 and ADT2 were able to complement the PDT knockout phenotype,
while ADT3-ADT6 were not. Although ADT6 displayed PDT function in the in vitro
biochemical assays, it had the lowest prephenate catalytic efficiency (Table 2),
and therefore it was understandable that it could not support growth in the in vivo
assays. Thus, it was concluded that ADT1 and ADT2 are preferentially
arogenate-accepting enzymes with low levels of prephenate recognition, and
ADT3-ADT6 are solely arogenate-accepting enzymes (Bross et al. 2011).

1.5 ADT and PDT domain organization
Domain structures have been defined for both the plant ADTs and the
bacterial PDTs (Cho et al. 2007)Figure 3). Both enzymes contain a catalytic
domain and a C-terminal ACT domain, which is named after three of the proteins
in its domain family (Aspartokinase, Chorismate mutase, TyrA).
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In bacterial PDTs, the catalytic domain binds the prephenate substrate
(Zhang et al. 2000; Hsu et al. 2004) and therefore it is hypothesized to be
involved in substrate-binding in plant ADTs as well. Typically, ACT domain
dimers bind specific amino acid ligands at their interface, resulting in the either
the activation of inhibition of enzymatic function (Aravind and Koonin 1999;
Liberles et al. 2005). ACT domain homologues are found in a wide range of
enzymes that are regulated by amino acids, such as valine-inhibited acetolactate
synthase, lysine-inhibited aspartokinase, and Phe-inhibited phenylalanine-4hydroxylase (Chipman and Shaanan 2001). In addition to the catalytic and ACT
domain, plant ADTs contain an N-terminal transit peptide. The transit peptide
was defined based on ~115 amino acids that don’t align with the bacterial PDTs
and has been shown to target ADTs to the chloroplasts (Cho et al. 2007; Bross
2011).
When comparing PDTs across bacteria species, the ACT domain is more
highly conserved than the PDT domain (Tan et al. 2008). When comparing the
six Arabidopsis ADTs, the catalytic and ACT domains are the most highly
conserved domains (62.0-97.8% and 61.5-91.7% similarity, respectively),
whereas the transit peptide sequences are far more diverse (Crawley 2004)
1.6 ADT and PDT 3D structure
Three crystal structures exist in the literature for bacterial PDTs (Tan et al.
2008; Vivan et al. 2008). These PDTs come from the bacterial species
Mycobacterium tuberculosis, S. aureus, and C. tepidum. Although these
enzymes have low protein sequence identity (32.22% overall) they have highly
similar overall 3D structures. The structures support the domain organization just
described (section 1.5). The catalytic domain is further divided into two
subdomains: the PDTa and PDTb subdomains, which are each comprised of a
central β-sheet in between three α-helices (Tan et al. 2008). The PDTb
subdomain is inserted within the PDTa via two linker regions, and in between
these two subdomains lies the catalytic cleft. This solvent accessible cleft is the
site of prephenate binding in the bacterial PDT. The ACT domain is connected to
the PDTa subdomain and interacts with this subdomain extensively.
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Figure 3. Schematic of the domain structure of plant ADTs and bacterial
PDTs.
Both the plant and bacterial enzymes contain a catalytic domain (blue) and a Cterminal ACT (Aspartokinase, Chorismate mutase, Tyr A) regulatory domain
(green). In addition, the plant enzymes contain an N-terminal transit peptide
(orange) for localization to the chloroplast.
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Figure 4. Ct-PDT monomer and dimer 3D conformation.
(A) Top: Ribbon drawing of the Chlorobium tepidum PDT monomer. The catalytic
domain is divided into two subdomains: the PDTa and PDTb subdomains. The
catalytic cleft is located in between the PDTa and PDTb subdomains and the
ACT domain is attached to the PDTa subdomain Bottom: schematic of the PDT
monomer in the closed (T) state (top view). (B) Top: Ribbon drawing of the
Chlorobium tepidum PDT homodimer, consisting of two monomers (blue and
red). The dimer is shown in the closed (T) state and two phenylalanine molecules
are shown bound to two pockets at the ACT dimer interface (beige). The catalytic
clefts are indicated in the aligned PDTa subdomains. Bottom: schematic of the
PDT dimer in the closed (T) state (top view). Original PDB file (2QMX) is from
Tan et al., 2008 and images are obtained from UCSF Chimera
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Two PDT monomers form a homodimer, the basic catalytic unit of the PDT
enzyme (Tan et al. 2008; Vivan et al. 2008), with extensive interactions across
both PDT and ACT domains (Figure 4B, top). The two catalytic clefts, one from
each PDT monomer, align to form an extended active site across the interface of
the PDT domain dimer (Tan et al. 2008). These clefts are in close proximity,
indicating that there may be some communication between the two active sites
during the decarboxylation/dehydration reaction. The ACT domains of the two
monomers also align, creating two hydrophobic pockets at the ACT dimer
interface. Two Phe molecules can simultaneously bind these hydrophobic
pockets. When Phe is absent, the dimer exists in an open (“Relaxed”) state in
which the prephenate substrate has access to the extended catalytic cleft formed
between the two monomers. However, the binding of the two Phe molecules to
the ACT dimer interface induces an overall conformational shift from this open
(R) state to a closed (“Tense”) state, in which access to the cleft is greatly
reduced (Tan et al. 2008; Figure 4, bottom; Figure 5). During this shift, the two
ACT domains move closer to each other. This conformational change is
propagated along the ACT-PDT interface, resulting in a shift in the PDT domains
as well. The two PDTb subdomains push towards each other and the two PDTa
subdomains move away from each other. This movement offsets the alignment
of the extended catalytic cleft, reducing the access of prephenate to and the
release of phenylpyruvate from the catalytic site and results in the allosteric
inhibition of enzymatic function. Interestingly, PDTs are also able to form
tetramers in solution, although the significance of these structures and their
involvement in the allosteric conformational change is not currently known (Tan
et al. 2008).
Although there are no crystal structures available for the plant ADTs, the
basic 3D structure of these enzymes can be estimated by homology modeling
against the known PDT protein structures. For example, the ADT5 monomer can
be modeled against the Ct-PDT monomer protein (Figure 6) using a 3D
homology modeling program called UCSF Chimera. This program predicts that
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Figure 5. Schematic of open (R) and closed (T) states of the PDT enzyme.
A schematic of the allosteric regulation mechanism that is triggered when
phenylalanine binds to the ACT domain interface of the bacterial PDT tetramer.
Shown is the PDT homodimer, made up of two monomers (blue and red; bottom
view). Binding of two phenylalanine molecules at the ACT interface between the
two dimers results in an overall conformation shift that affects substrate binding
in the catalytic sites of the complex. Adapted from Tan et al., 2008.
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Figure 6. 3D homology modeling of ADT5 and Ct-PDT.
(A) Ribbon diagram of the overlay of the PDT monomer from Chlorobium
tepidum (blue) and homology modeled ADT5 from Arabidopsis thaliana (pink).
(B) Ribbon diagram of homology modeled ADT5 (Model #1.2) from Arabidopsis
thaliana. Original Ct-PDT PDB file is from Tan et al., 2008; PDB: 2QMX, images
are obtained from UCSF Chimera and the homology modeled ribbon diagram
was created using UCSF Chimera’s “Modeller” program.
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although these two proteins share only 41.5% sequence identity, they have a
very similar overall monomer structure.

1.7 The importance of few amino acids
The diversity in the bacterial PDT sequences makes it difficult to
determine the amino acids that are important for prephenate substrate
recognition. As a consequence of this, the exact amino acids responsible for
prephenate recognition in plant ADTs are currently unknown. In Arabidopsis, two
of the six members of the ADT family display both ADT and PDT function.
Therefore, there must be some differences on the sequence level that can be
used to identify this.
Evidence in the literature suggests that enzymatic function can be
converted between two similar proteins by introducing only a few amino acid
substitutions to the protein sequence (Jäckel et al. 2008). This raises the
question of where to look within the Arabidopsis ADTs for the amino acids that
are responsible for PDT activity in ADT1 and ADT2. It seems intuitive that these
amino acids would be located within the catalytic cleft, the part of the protein that
is responsible for binding the substrate. However, it has been shown in other
studies that mutations do not need to be within a proposed catalytic site to affect
substrate specificity (Jeffery et al. 2000; Mendonça and Marana 2011).
Therefore, in order to be exhaustive, the entire ADT protein sequence must be
analyzed to find the amino acid(s) that can distinguish a prephenate-accepting
ADT from a solely arogenate-accepting ADT.

1.8 Thesis hypothesis and objectives
ADTs and PDTs have many similarities. They have similar domain
organization, they both catalyze a decarboxylation/dehydration reaction, and they
recognize substrates that differ by only the presence of a single amino group.
Due to these similarities, I hypothesize that PDT function can be introduced to an
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arogenate-only Arabidopsis ADT (ADT3-ADT6) through the alteration of only a
few amino acids. This research will identify the amino acid(s) that can distinguish
between a prephenate-accepting ADT like ADT1 and ADT2 and a solely
arogenate-accepting ADT like ADT3 – ADT6.
My first objective is to narrow down the domain (transit peptide, catalytic,
or ACT) that contains the sequences for prephenate recognition in the
Arabidopsis ADTs. This will be accomplished by generating ADT chimeras
containing domains from both a prephenate-accepting ADT (ADT1/ADT2) and an
arogenate-specific ADT (ADT3-ADT6). Since it has been demonstrated that
biochemical analysis may not reflect an in vivo system (Yao et al. 2007; Bross et
al. 2011), I will test for PDT function of these ADT chimeras in a pha2 yeast
complementation assay. Only chimeras with the domain that contains sequences
that can confer PDT function will be able to sustain growth of this PDT knockout
yeast strain.
Once the domain(s) have been identified, my second objective is to revisit
the sequence analysis and, through targeted amino acid substitutions and
another yeast complementation assay, identify the exact amino acid(s) that can
distinguish between a prephenate-accepting and a solely arogenate-accepting
ADT. I have chosen ADT2 (both arogenate- and prephenate-accepting) and
ADT4 and ADT5 (solely arogenate-accepting) for this research.

2 Materials and Methods
2.1 Media, buffers and gels
2.1.1 Media
For the creation of all solid media, 20 g of agar was added to 1 L of liquid
media.
Synthetic dextrose (SD) medium
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Per 1 L: 20 g glucose, 6.7 g yeast nitrogen base without amino acids,
1.5 g dropout powder (Amberg et al. 2005). Glucose was substituted with equal
weights of galactose or raffinose as required.
Yeast peptone dextrose (YPD) medium
Per 1 L: 20 g glucose, 10 g yeast extract, 20 g bacto-peptone (Amberg et
al. 2005).
Amino acid dropout powder
Per 25 L: 1 g adenine sulphate, 0.5 g L-arginine-HCL, 2.5 g L-aspartic
acid, 2.5 g L-glutamic acid, 0.75 g L-isoleucine, 1.5 g L-leucine, 0.75 g L-lysineHCL, 0.5 g L-methionine, 1.25 g phenylalanine, 9.35 g L-serine, 5 g L-threonine,
1 g L-tryptophan, 0.75 g L-tyrosine, 0.5 g uracil, 3.725 g L-valine (Sherman et al.,
1983), 2 mL histidine (His) liquid stock.
Drop-out powder containing the appropriate amino acids for selection and
functional testing were made from the above amino acids. 1.5 g of drop-out
powder was used per 1 L of SD medium before autoclaving.
Lysogeny broth (LB)
Per 1 L: 10 g bacto-tryptone, 5 g yeast extract, 10 g NaCl, 200 µL 5 N
NaOH (Sambrook and Russell 2001).
Super Optimal Catabolite-Repression (SOC) medium
Per 1 L: 20 g bacto-tryptone, 5 g yeast extract, 2 mL 5 M NaCl, 2.5 mL 5
M KCl, 10 mL 1 M MgCl2, 10 mL 1 M MgSO4, 20 mL 1 M glucose.
Antibiotics
Stock solutions of ampicillin (100 mg/mL), gentamycin (50 mg/mL) and
kanamycin (60 mg/mL) were prepared by dissolving each in double distilled
water. Dissolved antibiotics were filter sterilized (Sambrook and Russell 2001),
aliquoted and stored at -20°C. Stocks were added to the media after autoclaving
to a final concentration of 100 µg/mL, 15 µg/mL and 60 µg/mL for ampicillin,
gentamycin and kanamycin, respectively.
2.1.2 Buffers
5x Sodium dodecyl sulfate protein sample buffer
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Per 10 mL: 1.2 mL of 0.5 M Tris-HCl (pH 6.8), 2.5 mL 100% glycerol, 2 mL
10% sodium dodecyl sulfate (SDS), 0.25 mL β-mercaptoethanol (BME), 0.5 mL
2% (w/v) bromophenol blue, 3.55 mL double distilled water (Sambrook and
Russell 2001).
50x TAE buffer
Per 1 L: 242 g Tris base, 57.1 mL glacial acetic acid, 100 mL 0.5 M
ethylenediaminetetraacetic acid (EDTA) (pH 8.0), 1 L double distilled water. 50X
TAE buffer was diluted to 1X with sterile double distilled water before use.
Phosphate-buffered saline (PBS)/Tween-20
Per 1 L: 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4, 0.5 mL
Tween-20 (Sambrook and Russell 2001). pH was adjusted to 7.4 with HCl.
Yeast breaking buffer
Per 1 L: 500 mL of 0.1 M sodium phosphate (pH 7.4), 2 mL of 0.5 EDTA
(pH

8.0),

250

mL

of

phenylmethanesulfonylfluoride

20%

glycerol,

(PMSF),

238

10
mL

mL
double

of

100

distilled

mM
water

(pYEST2/NT vector manual, Invitrogen Cat. No. V8252-20).
2.1.3 Gels
Agarose separating gel
1% (w/v) agarose gels were used to separate and visualize PCR products
and fragments from restriction enzyme digests.
Per 30 mL: 30 mL 1x TAE buffer, 0.3 g of electrophoresis-grade agarose.
Stacking gel
10% (w/v) acrylamide separating gels were used to resolve proteins from
S. cerevisiae (Sambrook and Russell 2001).
Per 20 mL: 7.9 mL double distilled water, 6.7 mL 30% (w/v) acrylamide
mix, 5 mL 1.5 M Tris (pH 8.8), 0.2 mL 10% SDS, 0.2 mL 10% ammonium
persulfate (APS), 8 µL tetramethylethylenediamine (TEMED).
A 5% (w/v) stacking gel was also cast over the top of the 10% (w/v)
separating gel. This allowed the loaded sample proteins to be concentrated into a
tight band during the first few minutes of electrophoresis before entering the
separating portion of the gel.
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Per 10 mL: 6.8 mL water, 1.7 mL 30% acrylamide mix, 1.25 mL 1.0 M Tris
(pH 6.8), 0.1 mL 10% SDS, 0.1 mL 10% APS, 10 µL TEMED (Sambrook and
Russell 2001).

2.2 Strains and plasmids
2.2.1 Strains
E. coli DH5α and DH10β strains (Invitrogen Cat. No. 11319019 and
18290015, respectively) were used for maintenance and cloning of plasmid DNA.
Liquid cultures were grown at 250 RPM at 37°C in LB. Cells harboring plasmids
were grown in media supplemented with appropriate antibiotics for selection.
The “pha2” haploid PDT knockout S. cerevisiae strain (pha2: Matα,
his3Δ1, leu2Δ0, lys2Δ0, ura3Δ0, YNL316c::kanMX; Saccharomyces Genome
Database; Invitrogen Cat. No. YSC1021-549308) was used for complementation
assays. Yeast were grown at 30°C and liquid yeast cultures were grown at 220
RPM.
2.2.2 Plasmids
The full-length ADT genes were cloned into a modified pEZT-NL vector
(D. Ehrhardt, Carnegie Institution of Washington), where the 3’ GFP sequence
was replaced with a CFP sequence by a previous student in the lab to allow the
expression of a C-terminal CFP fusion protein (Bross et al. 2011). The inserts
contain a start codon and lack a stop codon, to allow for the continuous
expression of the CFP fusion protein.
The pDONRTM221 (Figure 7A; Invitrogen Cat. No. 12536-017) vector was
used as a donor vector. This vector contains an kanamycin marker for selection
in E. coli.
The pAG423GAL-ccdB-CFP yeast-compatible vector (Figure 7B; Alberti et
al. 2007) was used as a destination vector. This vector contains an ampicillin
resistance marker for selection in E. coli and a His marker for selection in S.
cerevisiae.
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Figure 7. Gateway® compatible donor vector and destination vector.
(A) Diagram of pDONRTM221 donor vector which contains attP sites for
recombination with the attB sites that flank the PCR product, to generate the
entry vector. Upon recombination, the ccdB gene is displaced by the gene insert.
The KanR resistance gene is used for selection of the recombined entry vector in
E. coli. (B) Diagram of the pAG423GAL-ccdB-ECFP destination vector. This
vector contains attR sites for recombination with the attL sites in the entry vector
to generate the expression vector. Upon recombination the ccdB gene is
displaced by the gene insert. The AmpR resistance gene is used for selection of
the recombined expression vector in E. coli and the HIS3 gene is used for
selection of yeast the recombined expression vector.
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2.3 Cloning procedure
Gateway® Cloning recombination technology was used to recombine the
ADT inserts into a yeast compatible destination vector following the
manufacturer’s manual (Invitrogen MAN0000282; Figure 8). Gateway® BP
Clonase® II Enzyme mix (Invitrogen Cat. No. 11789020) was used for the
recombination of the full-length ADTs and ADT chimeras into the pDONRTM221
vector to generate the entry vector. Gateway® LR Clonase® II Enzyme mix
(Invitrogen Cat. No. 11791100) was used for the recombination of the inserts into
the pAG423GAL-ccdb-ECFP yeast-compatible destination vector.

2.4 PCR amplification
2.4.1 Primer Design:
All

primers

were

tested

for

self-complementarity,

primer-pair

complementarity, balanced GC content and similar melting temperatures within
primer-pairs using DNAMAN (Lynnon BioSoft, Version 6; Table 3, Table 4).
2.4.2 Overlap extension PCR
Chimeras containing domains from both ADT2 and ADT4, or ADT2 and
ADT5 were generated through overlap extension PCR (Figure 9). All PCR
conditions were established using Tfi polymerase (Invitrogen Cat. No. 30342024)
prior to amplification with Platinum Taq High Fidelity Polymerase (Invitrogen Cat.
No. 11304011) (Table 5). PCR products were amplified using previously cloned
ADT full-length gene sequences as a template (Bross 2011), as previously stated
(section 2.2.2). Reactions were performed using a Touchgene Gradient
Thermocycler (Techne TC-512; Cat. No. 353.55144.E1).
Annealing temperatures varied based on the primers that were used in the
reaction (Table 3; Table 4), and therefore are denoted as X in Table 6.
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Figure 8. Schematic of Gateway® cloning strategy.
(A) Each construct is recombined into the pDONRTM221 vector (blue). This is
facilitated by the outer att recombination sites (orange) in a BP reaction,
generates an entry vector. (B) The insert is then recombined from the entry
vector into the pAG423GAL-ccdB-ECFP yeast compatible destination vector
(green) using the att recombination sites (orange) in an LR reaction. This
reaction generates an expression vector. Each expression vector is then
transformed into pha2 yeast for the complementation assay.
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Table 3. Primer sequences for domain swapping.

Annealing
Namea

Sequence (5’ to 3’)b

Directionc

Temperature
(°C)d

attB1-ADT2FL*

GGGGACAAGTTTGTACAAAAAAGCAGGCTTTATGGCAATGC

FWD

65

REV

65

FWD

65

REV

65

FWD

67

REV

67

ACACTGTT
attB2-ADT2FL*

GGGGACCACTTTGTACAAGAAAGCTGGGTAGAGCATTGTAG
TGTCCACTGG

attB1-ADT4FL*

GGGGACAAGTTTGTACAAAAAAGCAGGCTAGATGCAAGCCG
CAACGTCG

attB2-ADT4FL*

GGGGACCACTTTGTACAAGAAAGCTGGGTATGCTTCTTCTGT
GGATGTCATGG

attB1-ADT5FL*

GGGGACAAGTTTGTACAAAAAAGCAGGCTATGCAAACCATTT
CGCCTGCG

attB2-ADT5FL*

GGGGACCACTTTGTACAAGAAAGCTGGGTTTACGTCTTCGCT
AGGTAACG
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Table 3. (continued). Primer sequences for domain swapping.
Annealing
Namea

Sequence (5’ to 3’)b

Directionc

Temperature
(°C)d

ADT2/4CATACTF

GCACCGTTGCATGGTTCTAGTCTACGTGTTGCGTATCAGGG

FWD

59

REV

59

REV

59

FWD

59

FWD

59

AGTACGAGGT
ADT4/2TPR

TCGTACTCCCTGATACGCAACACGTAGACTAGAACCATGCA
ACGGTGC

ADT2/4TPCATR

GGCAGCAAAGACGATGCTAGTCTTGAAGAGTCTGTTAGTTC
CAGGGATAATGGG

ADT4/2ACTF

CCCATTATCCCTGGAACTAACAGACTCTTCAAGACTAGCAT
CGTCTTTGCTGCC

ADT2/4ACTF

CCTATAATCCCACGCACGGACCGGCCATTTAAGACAAGTAT
AGTTTTCTCGTTA
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Table 3. (continued) Primer sequences for domain swapping.
Annealing
Namea

Sequence (5’ to 3’)b

Directionc

Temperature
(°C)d

ADT2/4TPR

GGGAACGCCTTGGTAAGCTACACGAACGCGGGAGCCATT

REV

59

FWD

59

REV

67

FWD

62

REV

62

FWD

65

AGAGACAGA
ADT4/2CATACTF

TCTGTCTCTAATGGCTCCCGCGTTCGTGTAGCTTACCAAG
GCGTTCCC

ADT5/2MACTR

CCTCCAGATGCTCGGAGAGGATGTTTCCTATGCGGCCGCG
ATTCGATTTTCGTC

ADT2/5MACTF

TTGACGAAAATCGAATCGCGGCCGCATAGGAAACATCCTC
TCCGAGCATCTGGAGG

ADT2/5MACTR

CGCCTACGACTCTAAGGGGACAATTCTGTAAAGGGCGGC
TTTCAATCTTTGTGAG

ADT5/2MACTF

CTCACAAAGATTGAAAGCCGCCCTTTACAGAATTGTCCCG
TTAGAGTCGTAGGCG
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Table 3. (continued). Primer sequences for domain swapping.
Annealing
Namea

Sequence (5’ to 3’)b

Directionc

Temperature
(°C)d

ADT5/2MCATR

GGCTAAGCACCCTTCTCAAATCTTCAATACGAACTCCGGGA

REV

65

FWD

62

REV

65

FWD

67

AGAGCTAAGAGACAG
ADT2/5MCATF

CTGTCTCTTAGCTCTTCCCGGAGTTCGTATTGAAGATTTGAG
AAGGGTGCTTAGCC

ADT2/5TPR

AACTCCTTGATACGCGACACGAACGCGGGAGCCATTAGAGA
C

ADT5/2CATACT

TGTCTCTAATGGCTCCCGCGTTCGTGTCGCGTATCAAGGAG

F

TTC

ADT2/5TPCATR

GAAAACTATACTTGTCTTAAAGAGTCTGTTAGTTCCAGGGAT

REV

62

ADT5/2ACTF

ATTATCCCTGGAACTAACAGACTCTTTAAGACAAGTATAGTT

FWD

65

TTCTCG
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Table 3. (continued). Primer sequences for domain swapping.

Namea

Sequence (5’ to 3’)b

ADT2/5CATACTF

CGCCGTCTCATGGATCTACTCTTCGTGT

Directionc

Annealing
Temperature (°C)d

FWD

65

REV

65

FWD

62

REV

62

TGCGTATCAGGGAGTACG
ADT5/2TPR

TACTCCCTGATACGCAACACGAAGAGTA
GATCCATGAGACGG

ADT2/5ACTF

ATCATTCCCCGTACCGATCGTCCGTTTA
AGACAAGTATAGTTTTCTCG

ADT5/2TPCATR

AGAAAACTATACTTGTCTTAAACGGACGA
TCGGTACGGGGAATG

a

*: outer primer; bdouble underline: 5’ GGGG for docking of Gateway® enzymes; bold: attB1/attB2 sequences; bold and

underlined: added to maintain frame; italics: complementary to ADT2; underlined: complementary to ADT5; nonannotated: complementary to ADT4; cFWD: forward amplification; REV: reverse amplification. dAnnealing temperatures
listed for outer primers were used for full-length ADT and chimera amplification, and those listed for the inner primers
were used for overlap extension PCR.
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Table 4. Primer sequences for targeted mutagenesis.

Annealing
Name

Sequence (5’ to 3’)

a

b

Direction

Temperature
(°C)c

5-V397LF

CGCGTTAGCGGAGTTGCAAGAGTACACGTCATTCC

FWD

60

5-V397LR

GGAATGACGTGTACTCTTGCAACTCCGCTAACGCG

REV

63

4-V396LF

CGCGCTTGCGGAGCTTCAAGAGTACACGTCGTTCC

FWD

60

4-V396LR

GGAACGACGTGTACTCTTGGAACTCCGCAAGCGCG

REV

60

5-F341LF

GTGCTTTCCGCGTTTGCGCTTCGAAACATTAGTTTGACG

FWD

62

5-F341LR

CGTCAAACTAATGTTTCGAAGCGCAAACGCGGAAAGCAC

REV

62

5-S345NF

GCGTTTGCGTTTCGAAACATTAATTTGACGAAAATCGAATCG

FWD

64

CGGCCG
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Table 4. (continued). Primer sequences for targeted mutagenesis.

Annealing
Name

Sequence (5’ to 3’)

a

b

Direction

Temperature
(°C)c

5-S345NR

CGGCCGCGATTCGATTTTCGTCAAATTAATGTTTCGAAACGCA

REV

64

FWD

64

REV

64

AACGC
5-DM-F

GTGCTTTCCGCGTTTGCGCTTCGAAACATTAATTTGACGAAAA
TCGAATCGCGG

5-DM-R

CCGCGATTCGATTTTCGTCAAATTAATGTTTCGAAGCGCAAAC
GCGGAAAGCAC

a

Bold and double-underlined: nucleotide substitutions; Underlined: complementary to ADT5; non-underlined:

complementary to ADT4; bFWD: forward amplification; REV: amplification. These primers were used in combination with
the outer primers listed in Table 2. cAnnealing temperature for overlap extension PCR.
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Figure 9. Schematic of overlap extension PCR.
(A) Fragments containing 15-24 bp of overlapping sequences are generated in a
first set of PCRs using outer primers that are specific to the template (straight
arrows) and inner primers that contain a combination of sequences from both of
the ADT templates (curved arrows). (B) In a third PCR reaction, both fragments
that were generated in (A) are used as templates. The overlapping sequences
facilitate the annealing of the fragments, and the DNA polymerase extends from
the fragments’ 3’ ends, generating the full-length sequence. Only the outer
primers are used in this reaction, ensuring that the full-length chimera is
amplified.
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Table 5. Components for fragment amplification and overlap extension
PCR.

Component

Final Concentration

10 High Fidelity PCR Buffer

1X

10 mM MgSO4

2.0 mM

10 mM dNTP Mix

0.2 mM each

10 µM Forward Primer

0.2 µM

10 µM Reverse Primer

0.2 µM

Template DNA*

<500 ng

Platinum® Taq DNA Polymerase

1 U/rxn

High Fidelity (5 U/µL)
Autoclaved, distilled water

-

*For overlap extension PCR reactions: the two templates to be recombined were
both added to this final concentration.
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Table 6. Thermocycler conditions for fragment amplification and overlap
extension PCR.

Cycle

Temperature (°C)

Time

Number of
Cycles

Initial denaturation

94

10 min

Denature

94

15 secs

Annealing

55

30 secs

Extension

72

1 min

Denature

94

15 secs

Annealing

X

30 secs

Extension

72

1 min

Final extension

72

7 min

1

5*

30

1

*For 5-SLEEG and 5-F341L overlap extension PCR: the number of cycles for
these PCR reactions was increased to 10 and primers were not added until after
these 10 cycles were complete.
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The 5-SLEEG and 5-F341L full-length constructs (see section 2.5 for more
information on these chimeras) could not be successfully amplified through overlap extension PCR with the standard cycle conditions, and so a modified protocol
was used. In this modified protocol, the number of cycles at a 55°C annealing
temperature was increased from five to ten, and primers were only added to the
reaction after these cycles were complete (Table 6). This was done to ensure
that the overlapping sequences would anneal first and the DNA polymerase
would extend from the 3’ ends of the fragments, generating the full-length
product. Then, once the primers were added, this full-length product was used as
the template.
M13 primers were used for sequencing all of the ADT inserts in the entry
vectors.

2.5 Chimera name annotation
The chimeras are named based on the protein sequences. All descriptions
and positions correspond to the amino acid level.
The six chimeras that contained domain sequences from ADT2 and ADT4
were the first six chimeras to be generated, and therefore these constructs are
named Chimera 1 – Chimera 6 (Figure 10). The next seven chimeras that were
generated contained domain sequences from ADT2 and ADT5 and were named
Chimera 7 – Chimera 13 (Figure 11).
The chimeras that swap the nucleotides that correspond to the SLEEG
motif in the ACT domain of ADT2 and ADT5 were named 2-SLEEG and 5SLEEG, respectively. 2-SLEEG has the nucleotide sequences that correspond to
the entire ADT2 transit peptide and catalytic domain, and the N-terminal ACT
domain sequence until G299, ADT5 sequences from the corresponding ADT5
amino acid (S331) make up the C-terminal end of the ACT domain in this
chimera. 5-SLEEG has the nucleotide sequences that correspond to the entire
ADT5 transit peptide and catalytic domain, and the N-terminal ACT domain
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Figure 10. Schematics for ADT2/ADT4 chimeras.
Full-length ADT2 (white) and ADT4 (purple) were assembled through overlap
extension PCR to generate Chimera 1 – Chimera 6, which have every possible
combination of the three ADT domains.
TP: transit peptide; CAT: catalytic domain; ACT: ACT regulatory domain.
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Figure 11. Schematics for ADT2/ADT5 chimeras.
Full-length ADT2 (white) and ADT5 (green) were assembled through overlap
extension PCR to generate Chimera 7 – Chimera 13 which have every possible
combination of the three ADT domains.
TP: transit peptide; CAT: catalytic domain; ACT: ACT regulatory domain.
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sequences until S331 and ADT2 sequences make up G299 to the C-terminal
ACT domain (Figure 12).
The chimeras that contain the nucleotide mutations that result in a single
amino acid substitution are named as follows: (the ADT template) – (native
amino acid) (position) (substituted amino acid). For example, the chimera named
5-F341L contains the nucleotide sequences that express the transit peptide,
catalytic and ACT domains from ADT5 with the exception that a Phe has been
substituted for a Leu at amino acid position 341 (Figure 12).
For the overlap extension PCR, the fragments that contain overlapping
sequences for the amplification of the ADT construct are named “Fragment Xa”
or “Fragment Xb”, where X represents the chimera number or name. For
example, the overlapping fragments that were used as templates to generate
Chimera 1 through overlap extension PCR are named Fragment 1a and
Fragment 1b.

2.6 Gel purification and quantification of DNA
DNA fragments were size separated by gel electrophoresis on a 1% (w/v)
agarose gel in TBA buffer. The DNA was stained with RedSafeTM Nucleic Acid
Staining Solution (FroggaBio Cat. No. 21141) and visualized under UV light.
Fragments of the correct size (Table 7; Table 8; Table 9) were excised from the
gel and were purified using the PureLink Quick Gel Extraction Kit (Invitrogen Cat.
No. K210012). Samples were resuspended in 50 µL of Elution Buffer (“E5”
provided in the kit; 10mM Tris-HCL, pH 8.5) and the DNA concentration and the
260/280 values were measured using a NanodropTM 1000 Spectrophotometer
(Thermo Scientific Cat. No. ND-1000). DNA fragments were considered
acceptable for use in PCR or cloning if the concentration was between 25 and
75 ng/µL and the 260/280 values were between 1.7 and 1.9.
If sample concentration was between 10 ng/µL and 25 ng/µL, samples
were evaporated using a ScientificTM SavantTM DNA SpeedVacTM Concentrator
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Figure 12. Schematics for N-terminal ACT domain constructs.
Overlap extension PCR was used to generate 2-SLEEG, 5-SLEEG, 5-F341L, 5S345N, 5-DM, 5-V397L, and 4-V396L constructs using ADT2, ADT4, and ADT5
templates.
TP: transit peptide; CAT: catalytic domain; ACT: ACT regulatory domain.
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Table 7. Composition and expected lengths of ADT2/ADT4 chimeras.

Fragments and
Chimeras

Fragment 1a

ADT2 Domains

nt

TP

315

Fragment 1b
Fragment 2a

CAT, ACT
CAT, ACT

918
867

Fragment 2b
Fragment 3a

Length

ADT4 Domains

TP
TP, CAT

393
813

Fragment 3b

ACT

354

Fragment 4a

TP, CAT

329

Fragment 4b

ACT

Fragment 5a

CAT

957

Fragment 5b
Fragment 6a

TP

Fragment 6b

ACT

TP

1020

ACT

296

CAT

341
1011

	
  

aa

MWa
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Table 7. (continued). Composition and expected lengths of ADT2/ADT4
chimeras.

Fragments and

ADT2 Domains

nt

aa

MWa

1146

381

42.1

TP, CAT, ACT

1275

424

45.9

Chimeras

FL ADT2

Length

ADT4 Domains

TP, CAT, ACT

FL ADT4
Chimera 1

TP

CAT, ACT

1197

398

43.8

Chimera 2

CAT, ACT

TP

1224

407

44.3

Chimera 3

TP, CAT

ACT

1291

396

43.8

Chimera 4

ACT

TP, CAT

1210

409

44.3

Chimera 5

CAT

TP, ACT

1300

422

46

Chimera 6

TP, ACT

CAT

1292

384

44.1

Amino acid length and molecular weight are only listed for chimeras used in the
Western Blot. nt: nucleotide length; aa: amino acid length; MWa : molecular mass
in kDa of the native protein. Add 27.7 kDa to this value for the molecular weight
of the ADT-ECFP fusion protein.
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Table 8. Composition and expected lengths of ADT2/ADT5 chimeras.

Fragments and
Chimeras

Fragment 7a

ADT2 Domains

nt

TP

297

Fragment 7b
Fragment 8a

CAT, ACT
TP, CAT
ACT
CAT, ACT

336
995

Fragment 9b
Fragment 10a

900
795

Fragment 8b
Fragment 9a

Length

ADT5 Domains

TP
ACT

278
341

Fragment 10b

TP, CAT

962

Fragment 11a

TP, CAT, N-ACT

1071

Fragment 11b

ACT-C

237

Fragment 12a

TP, CAT, N-ACT

1039

Fragment 12b

ACT-C

264

Fragment 13a

TP, N-CAT

660

Fragment 13b

CAT-C, ACT

600

	
  

aa MWa
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Table 8. (continued). Composition and expected lengths of ADT2/ADT5
chimeras.
Fragments and
Chimeras

FL ADT2

ADT2 Domains

Length

ADT5 Domains

aa

MWa

1146 381

42.1

TP, CAT, ACT

1278 425

45.9

nt

TP, CAT, ACT

FL ADT5
Chimera 7

TP

CAT, ACT

1217 398

43.5

Chimera 8

TP. CAT

ACT

1361 396

43.7

Chimera 9

CAT. ACT

TP

1267 408

44.5

Chimera 10

ACT

TP, CAT

1203 410

44.3

Chimera 11

ACT-C

TP, CAT, N-ACT

1328 411

44.5

Chimera 12

TP, CAT, N-ACT

ACT-C

Chimera 13

CAT-C, N-ACT

TP, N-CAT

1223 367 40.31
1210 355

38.4

Amino acid length and molecular weight are only listed for chimeras used in the
Western Blot. nt: nucleotide length; aa: amino acid length; MWa : molecular
weight in kDa of the native protein. Add 27.7 kDa to this value for the molecular
weight of the ADT-ECFP fusion protein; N-: N-terminal sequences; -C: C-terminal
sequences.
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Table 9. Composition and expected lengths of ACT domain chimeras.

Fragments and
Chimeras

ADT2 Domains

ADT4 Domains

Length

ADT5 Domains
nt

5-F341La

ACT-Cb

306

5-F341Lb

TP, CAT, N-ACTb

994

5-S345Na

TP, CAT, N-ACTc

1084

5-S345Nb

ACT-Cc

226
d

5-DMa

TP, CAT, N-ACT

1092

5-DMb

ACT-Cd

232

5-SLEEGa

ACT-Ce

1052
TP, CAT, N-ACTf

5-SLEEGb
2-SLEEGa

TP, CAT, N-ACTg

267
270

ACT-Ch

2-SLEEGb
i

1117

4-V396La

TP, CAT, N-ACT

1207

4-V396Lb

ACT-Ci

146
TP, CAT, ACTj

5-V397La

	
  

1216

aa

MWa
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Table 9. (continued). Composition and expected lengths of ACT domain chimeras.
Fragments and
Chimeras

ADT2 Domains

ADT4 Domains

Length

ADT5 Domains
nt

ACT-Cj

5-V397Lb

aa

MWa

168

5-F341L

b

TP, CAT, ACT

1278

425

46.0

5-3S45N

TP, CAT, ACTc

1278

425

46.0

5-DM

TP, CAT, ACTd

1278

425

45.9

5-SLEEG

ACT-C e

TP. CAT. N-ACTf

1269

412

44.6

2-SLEEG

TP, CAT, N-ACTg

ACT-Ch

1236

394

43.5

1275

424

46.0

1278

425

46.0

TP, CAT, ACTi

4-V396L

j

5-V397L

TP, CAT, ACT

Amino acid length and molecular weight are only listed for chimeras used in the Western Blot. nt: nucleotide length; aa:
amino acid length; MWa molecular weight in kDa of the native protein. Add 27.7 kDa to this value for the molecular weight
of the ADT-ECFP fusion protein; N-: N-terminal sequences; -C: C-terminal sequences; b: sequences with 1021T>C
substitution; c: sequences with 1034G>A substitution; d: sequences with both 1021T>C and 1034G>A substitutions; e:
sequences from 898G to C-terminus; f: sequences from N-terminus to 1012G; g: sequences from N-terminus to 898G; h:
sequences from 1012G to C-terminus; i: sequences with 1186G>T substitution; j: sequences with 1189G>C substitution.
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(Thermo Scientific Cat. No. 20-548-132) and resuspended in sterile double
distilled water to increase the concentration to within the acceptable range.

2.7 Plasmid DNA isolation, DNA sequencing and analysis
Plasmid DNA was isolated from DH5α E. coli using an alkaline lysis with
SDS miniprep protocol (Sambrook and Russell 2001). Plasmid DNA for
sequencing was isolated using the QIAprep Spin Miniprep Kit (QIAGEN Cat. No.
12123). Isolated DNA concentration and quality was analyzed using NanodropTM
1000 Spectrophotometer (Thermo Scientific Cat. No. ND-1000).
Entry vectors were sent to the London Regional Genomics Centre in the
Robarts Research Institute for sequencing and only inserts lacking mutations
were used for functional analysis (The University of Western Ontario).

2.8 Transformations
2.8.1 E. coli transformations
DH5α E. coli cells were made chemically competent through a Rubidium
Chloride Competent Cell procedure (Renzette 2011) and plasmid DNA was
transformed into the competent E. coli cells using the One Shot® TOP10
Chemically Competent E. coli transformation procedure (Invitrogen Cat. No.
C4040-03 Manual). All liquid cultures of E. coli were grown at 37°C and 225 RPM
unless otherwise stated. Alterations to the transformation procedure were as
follows: incubation time in a 37°C shaker was increased to 1.5 hours immediately
following the heat shock, and the amount of cells plated on solid selective LB
was increased to 250 µL.
Transformed E. coli cells were plated on solid selective LB plates and
incubated at 37°C overnight. Colonies were picked the next day and grown
overnight in liquid selective LB. Bacterial stocks were stored in 25% sterile
glycerol at -80°C.
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2.8.2 pha2 yeast transformations
S. cerevisiae pha2 cells were made competent and transformed using the
lithium acetate/single stranded carrier DNA/polyethylene glycol method (Gietz
and Woods 2002). Yeast was transformed with one of the following: an ADT
chimera, full-length ADT2, ADT4 or ADT5, or the empty pAG423GAL-ccdBECFP destination vector. Cells were plated on appropriately supplemented solid
selective SD media and incubated at 30°C for 3 to 7 days. Yeast colonies were
then re-streaked on the same type of media, incubated at 30°C for 3 more days,
and were stored in 15% (w/v) sterile glycerol at -80°C. For all yeast experiments,
cell density was determined by counting yeast cells using a Bright-LineTM
Haemacytometer (Sigma-Aldrich Cat. No. Z359629).

2.9 Protein induction, isolation and detection in S. cerevisiae
A Western blot assay was used to determine if the pha2 yeast was able to
express the ADT proteins. Samples for this assay included yeast that contained
the ADT chimeras, ADT2, ADT4 or ADT5 full-length proteins, or the empty
destination vector, untransformed yeast, and non-induced yeast which contained
Chimera 8 but what grown in non-inducing medium. All yeast cultures were
grown in liquid media at 30°C and 225 RPM unless otherwise stated.
First, pre-cultures of the yeast samples were grown in appropriately
supplemented non-inducing liquid media (raffinose; West Jr et al. 1984) for 24
hours. The cells were harvested in mid-late logarithmic growth phase (~7 x 106 -7
x 107) by centrifuging at 1500 x g for 5 minutes. They were then transferred to
appropriately supplemented inducing liquid media (galactose; West Jr et al.
1984), with the exception of the non-induced sample which was transferred to
appropriately supplemented non-inducing liquid media (glucose; West Jr et al.
1984). They were grown for approximately 24 hours and cells were collected at a
cell density of 5 x 106 cells/mL. Cell lysates were prepared according to the
manufacturer’s instruction manual for the pYES2/NT vector (Invitrogen Cat. No.
V8252-20). The total soluble protein (TSP) was quantified using a PierceTM BCA
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Protein Assay Kit (Pierce Cat. No. 23227; Smith et al. 1985) and samples were
diluted to 750 µg/mL of protein and stored at -80°C in 5X denaturing SDS buffer
with BME until the Western blot assay.
Fifteen µg of TSP from each sample was size separated on a 10%
(w/v) SDS-PAGE. A Precision Plus ProteinTM Dual Color Standards ladder
(BioRad Ca. No. 161-0374) and a GFP-hydrophobin standard (1:1000 dilution;
Gutiérrez et al. 2013) were also loaded. The proteins were transferred to a
nitrocellulose membrane (Invitrogen Cat. No. LC2000) using a semi dry transfer
method (Towbin et al. 1979) and probed with primary anti-GFP antibody (1:5000
antibody dilution of A.v. monoclonal antibody (JL-8), Clontech Cat. No. 632380).
The anti-GFP antibody was used because CFP and GFP are similar enough that
both can be detected with this antibody (Bross et al. 2011). Subsequently, the
blot was probed with a goat anti-mouse IgG (H+L)-horseradish peroxidase
conjugated antibody (1:3000 dilution, Bio-Rad Cat. No. 170-6516). An enhanced
chemiluminescence (ECL) detection system (GE Healthcare Cat. No. RPN2109)
was used for visualization. Western blots were exposed for 1 minute and imaged
using X-ray film.

2.10 Yeast complementation assays
PDT activity was tested for in a pha2 yeast complementation assay
(Figure 13). The yeast samples described in the previous section (section 2.7)
were grown in appropriately supplemented liquid raffinose media for 24 hours
and were harvested at a cell density of at least 5 x 106 cells/mL. All liquid yeast
cultures were grown at 30°C and 225 RPM unless otherwise stated. Aliquots of
each were then centrifuged at 13000 x g for 30 seconds and resuspended in
sterile double distilled water to a final concentration of 1 x 105 cells/mL.
All samples and controls were tested on plates of solid SD media. These
plates contained either glucose (which represses the GAL1 promoter in the
destination vector), raffinose (which neither represses or induces GAL1) or
galactose (which induces GAL1) as a carbon source. Plates within each carbon
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Figure 13. Schematic of complementation assay to test for PDT function.
(A) ADT chimeras are recombined into the yeast compatible destination vector.
pha2 yeast are transformed with the destination vector carrying an ADT insert.
(B) Yeast transformants are spotted on selective solid SD media containing
galactose as a carbon source to induce transcription (right-facing arrow) from the
GAL1 promoter (light green). The yeast transformants were spotted on solid SD
media containing Phe as a positive control (green checkmark). Transformants
were spotted on solid selective SD media lacking Phe to test for PDT function
(purple question mark). Note: yeast transformants were also spotted on solid SD
media containing glucose or raffinose as a carbon source.

	
  

	
   63	
  

A
HIS3!

AmpR!
ECFP!

pAG423GAL1ccdB1
ECFP!

attR2!
ccdB!

B

GAL1!
attR1!

+"Galactose"
+"Phenylalanine""

+"Galactose"
1"Phenylalanine""

✔

?"
	
  

	
   64	
  
source were divided into three treatments: one that was fully-supplemented, one
which selected for transformed yeast (lacking His), and one which tested for PDT
function (lacking His and Phe). pha2 transformant liquid cultures of 10 µL were
spotted on each plate and growth was documented for 30 days.

2.11 3D Homology Modeling
UCSF Chimera was used for all molecular graphics and analyses presented
in this study. The UCSF Chimera program was developed by the Resource for
Biocomputing, Visualization and Informatics and the University of California, San
Francsisco and is supported by NIGMS (P41-GM103311).
To predict the structure and the position of the amino acids for distinguishing
between a prephenate –accepting ADT and a solely arogenate-accepting ADT,
in ADT2 and ADT5, the ADT2 and ADT5 protein sequences were homology
modeled against a protein template with a known structure. Chimera’s “BLAST
Protein” tool was used to identify the protein structure that has the highest
similarity to ADT2 and ADT5. The ADTs were modeled to Chain A of the PDT
protein from C. tepidum (PDB file 2QMX_A; Tan et al. 2008) using the “Modeller”
tool. The program used two scores, a GA341 and a zDOPE score, to measure
the quality of the models that were generated with this tool. The GA341 model
score is derived from statistical potentials and a value greater than 0.7 generally
indicates a reliable model (>95% probability of having the correct fold (Pettersen
2004). The zDOPE score, also known as the Discrete Optimized Protein Energy
(DOPE) score, is a sample of native structures that do not depend on adjustable
parameters and is based on an improved reference state that accounts for the
spherical shape of the native structures. This score is used to derive an atomic
distance-dependent statistical potential from a sample of native structures and a
more negative zDOPE score indicates a better model (Pettersen 2004).
Amino acid substitutions were made using the Chimera’s “Rotamers” tool and
the Dunbrack Rotamer library (Dunbrack Jr 2002). Interatomic “clashes”
(unfavourable interactions in which atoms are too close together) and “contacts”
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(both polar and nonpolar interactions) were found in atoms with a Van der Waal
radius overlap of greater than or equal to 0.6 Ångstroms using the “Clashes &
Contacts” tool. The “FindHBond” tool was used to identify potential hydrogen
bonds between the amino acids of interest and their surrounding amino acids.

3 Results
3.1 in silico analysis of ADTs and PDTs
An in silico approach was used to identify amino acids that can potentially
differentiate between the prephenate-accepting and the solely arogenateaccepting ADTs. To do this, both ADT and PDT protein sequences were
analyzed and compared.
First, PDT protein sequences were selected from 26 different bacterial
species (Table 1). These 26 bacteria were chosen so that they represent a
diverse set of species. For example, sequences from both Gram-negative and
Gram-positive bacteria were included. In contrast to Arabidopsis and other plant
species that have ADT families, bacteria contain only one PDT. The goal of this
alignment was to identify amino acids that were common to the PDTs. It was
assumed that if an amino acid was important for PDT function it would be
conserved among the bacterial PDTs in this alignment. However, there is a high
level of sequence diversity between the bacterial sequences. For example, some
sequences chosen for the alignment were only 24.6% identical, and there was an
average of 45.8% identity within the entire group. Amino acids that were identical
in 100% of the sequences were in highly conserved motifs that are known to be
important for overall enzyme function (data not shown), and therefore unlikely to
distinguish between an ADT and a PDT. Therefore, 100% identity was
considered to be too stringent. Instead, amino acids that were similar in more
than 75% of the sequences were identified. Forty amino acids were identified and
are highlighted in blue in Figure 14.
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Figure 14. Protein sequence alignment of bacterial PDTs.
Alignment of 27 PDT protein sequences from bacteria generated with DNAMAN.
Dots: spacing introduced by the DNAMAN alignment program; blue highlight: 40
amino acid locations that were identified as similar in more than 75% of the
bacterial sequences; yellow highlight: the 16 of 18 amino acid sites identified in
the Arabidopsis ADT alignment that could be located; star: the 10 amino acid
sites identified in the Arabidopsis ADT alignment that contained both the amino
acid from ADT1/ADT2 and the amino acid from ADT3 – ADT6; arrow: the 6
amino acid sites identified in the Arabidopsis ADT alignment that did not contain
the amino acid found in ADT3 – ADT6; green arrow: the amino acid position that
corresponds to the Phe341Leu substitution in ADT5 (discussed in section 3.5).
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Bant
Bant
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Bhal
Bhal
Linn
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Lmon
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Efae
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Rmel
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Mmar
Magn
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Ctep
Drad
Drad
Ecol
Ecol
Styp
Styp
Eher
Eher
Hinf
Hinf
Vcho
Paer
Paer
Pstu
Pstu
Tten
Tten
Saur
Saur

RVGYLGPEATFTNMAVSRFFP....EAEHVPYRTIPDCMDAAANGNVDYAVVPLENAIEGSVNITVDYLVH.EQP
KVGYLGPAATFTHLAVSSCFQN...GAEHVAYRTIPECIDAAVAGEVDFAFVPLENALEGSVNLTIDYLIH.EQP
KIGYLGPRGTFTEMAVQTLFDD...KNVLKPYRTIPDCMDSVANGDMDAAVVPVENAIEGSVNVTLDYLIH.KQR
KIAYLGPAASFTHAAAAKAFP....KEEMVAKSTIPDCIMAIEKEDVDVAVVPIENTIEGSVNITLDYLFH.FSS
KIAYLGPAASFTHSAAAKAFP....KEEMIAKSTIPDCIMAIEKEDVDVAVVPIENTIEGSVNITLDYLFH.FSS
KVGYLGPIGSFTYSATLAAFP....EATLMPYASIPACLKAIEQQEVAWSIIPIENTIEGTVNASIDYLYH.QAQ
KIAYLGPRGSFCSVVAETAFV....SEELFAYDSILDVIEAYDEGKCDFALVPIENSTEGTVNMSIDKIFH.DSK
KIAYLGPKGSFSHHVVQTAFP....HEELQAFANITDVIKAYEQGLVNYSVVPVENSIEGSVHETLDYLFH.QAH
RIAFQGEFGANSDMACR.DM...FPDMEPLPCPTFEDAFNAIENGEADLGMIPIENTLAGRVADIHHLLP..ESR
RISFQGDYGANSDMACR.DM...FPSMEPLPCQTFEDAFLAVENGEADLAMIPIENTIAGRVADIHHLLP..ESR
RISFQGEAGANSDTACR.NM...FPDMEPLPCPTFEDAFNAVETGAADLAMIPIENTLAGRVADIHYLLP..LAD
RISFQGEPGANSDTACR.NV...YPSMEPLPCPTFEDAFNAVETGKADLAMIPIENTIAGRVADIHHLLP..ESR
KIAFQGEPGANSHIAIV.EA...YPDAEPMPCATFEDALSAISSGEADLGMIPIENSVAGRVADIHHLLP..ASG
KIAFQGEPGANSHIAIS.DA...YPTAEAMPCATFEDALSAISSGEADLGMIPIENSVAGRVADIHHLLP..TSK
SIAFQGEPGAYSHLACR.NA...YPGMQPLPCATFEDTFAAVREGRARYAMIPIDNSVAGRVADVHHLMP..YAG
VVAFQGAHGAYSEQACR.EK...LPGYQSRPYKTFEDIFIAVEQGDAELGMLPVENSMAGVVSDSYDLLA..VHN
LIAYQGEPGAYSEIAAL.......RFGEPLPCESFDDVFSAVTEQKADYAVIPIENSLGGSIHQNYDLLL..RRP
AVAFQGNPGSYGEIAALNAL...PQVRETLGYPTFHEVARAVENGEADYGVLPVENSLMGAIHQSIDLLT..ETE
RIAFLGPKGSYSHLAARQYAARHFEQFIESGCAKFADIFNQVETGQADYAVVPIENTSSGAINDVYDLLQ..HTS
RIAFLGPKGSYSHLAARQYAARHFEQFIESGCAKFTDIFHQVETGQADYAVVPIENTSSGAINDVYDLLQ..HTS
RIAFLGPKGSYSHLAARNYASRHFDSMVECGCLKFHDIIKQVENGVADYAVMPIENTSSGSINDVYDLLQ..QTS
HIAFLGKRGSYSNLAARNYAARYQKQFVELGCQSFEQVFEKVQTGEADFGVLPLENTTSGAINEVYDLLQ..HTD
RVAFLGAKGSYSHLATREYFSRKNTELIELNCDHFKEVARTVESGHADYGVLPIENTSSGSINEVYDLLQ..HTT
KVAYLGPEGTFTQAAALKHFG...NAVISTPMAAIDEVFREVAAGAVNFGVVPVENSTEGAVNHTLDSFL..EHD
RVAYLGPEGTFSQAAALKHFG...HSVISKPMAAIDEVFREVVAGAVNFGVVPVENSTEGAVNHTLDSFL..EHD
KVGYLGPKGTFSEEAVFKYIEG.MKECEAIEFATIQDVVKSVAEGTCDEGILPVENSIEGSVNVSLDLLINDAEG
QLYYLGPKGTFSYLACRQYFS..ENEATFQPKSNLFEVIKAVADDDTSIGVVPIENSIEGTINIVADALA..QQD

7270
7171
7171
7170
7170
7070
7170
7170
7569
7569
7669
7569
7369
7069
7869
7069
7066
7070
7373
7473
7373
7373
7473
7170
7170
8174
7271

Bant
Bsub
Bhal
Linn
Lmon
Efae
Llac
Spne
Atum

LSIVGEITVPIQQHLLVHPQYADVWEEVYAVHSHPHAIAQCHKFLNEELKGVTARDMTSTSAAAQYVKEHPEEKI
LPIVGEMTLPIHQHLLVHPSRENAWKELDKIYSHSHAIAQCHKFLHRHFPSVPYEYANSTGAAAKFVSDHPELNI
LEIVADIVVPISQHFLVHPNQRD..NEIKKILSHPHAVAQCHEFLRSSYPGVEIEYMTSTAAAAQWVADHPNEPV
VPVVAEIVLPIAQHLMVHPAHKATWKSVQKVMSHPQALAQCHTFLQAELYGVEREVTPSTAYAAKWVSNNPTELV
VPVVAEIVLPIAQHLMVHPAHVSAWKSVQKVMSHPQALAQCHTFLQAELYGVEREVTPSTAYAAKWVSNNPTELV
LPVQAELVLPIQQQLMVAKENQAIWQQSQKILSHPQALAQSQMFLEKNFPEAILEATPSTAYAAKYIAEHPELPF
ATVVAEFVLPISQNLLALSKE....GKIEHIYSHPQALAQTRNYLREHYPQAKVEITDSTSAAAEFVKNHPDLPI
	
  
IQAVAEIVQPIHQQLMVVPGH....TKIEKIFSHPQALAQGKKFIDEQYPEAQIEVTASTAYAARFISEHPDQPF
LHIIGEYFMPIRFQLMVVPGVTK..DEIRTVHSHIHALGQCRKIIRSN..GWKPVIAGDTAGSARLVSEKGDRSM

145
146
144
145
145
145
141
141
140

Bjap
Rpal
Mmag
Magn
Ctep
Drad
Ecol
Styp
Eher
Hinf
Vcho
Paer
Pstu
Tten
Saur

KIAFQGEPGANSHIAIV.EA...YPDAEPMPCATFEDALSAISSGEADLGMIPIENSVAGRVADIHHLLP..ASG
KIAFQGEPGANSHIAIS.DA...YPTAEAMPCATFEDALSAISSGEADLGMIPIENSVAGRVADIHHLLP..TSK
SIAFQGEPGAYSHLACR.NA...YPGMQPLPCATFEDTFAAVREGRARYAMIPIDNSVAGRVADVHHLMP..YAG
VVAFQGAHGAYSEQACR.EK...LPGYQSRPYKTFEDIFIAVEQGDAELGMLPVENSMAGVVSDSYDLLA..VHN
LIAYQGEPGAYSEIAAL.......RFGEPLPCESFDDVFSAVTEQKADYAVIPIENSLGGSIHQNYDLLL..RRP
AVAFQGNPGSYGEIAALNAL...PQVRETLGYPTFHEVARAVENGEADYGVLPVENSLMGAIHQSIDLLT..ETE
RIAFLGPKGSYSHLAARQYAARHFEQFIESGCAKFADIFNQVETGQADYAVVPIENTSSGAINDVYDLLQ..HTS
RIAFLGPKGSYSHLAARQYAARHFEQFIESGCAKFTDIFHQVETGQADYAVVPIENTSSGAINDVYDLLQ..HTS
RIAFLGPKGSYSHLAARNYASRHFDSMVECGCLKFHDIIKQVENGVADYAVMPIENTSSGSINDVYDLLQ..QTS
HIAFLGKRGSYSNLAARNYAARYQKQFVELGCQSFEQVFEKVQTGEADFGVLPLENTTSGAINEVYDLLQ..HTD
RVAFLGAKGSYSHLATREYFSRKNTELIELNCDHFKEVARTVESGHADYGVLPIENTSSGSINEVYDLLQ..HTT
KVAYLGPEGTFTQAAALKHFG...NAVISTPMAAIDEVFREVAAGAVNFGVVPVENSTEGAVNHTLDSFL..EHD
RVAYLGPEGTFSQAAALKHFG...HSVISKPMAAIDEVFREVVAGAVNFGVVPVENSTEGAVNHTLDSFL..EHD
KVGYLGPKGTFSEEAVFKYIEG.MKECEAIEFATIQDVVKSVAEGTCDEGILPVENSIEGSVNVSLDLLINDAEG
QLYYLGPKGTFSYLACRQYFS..ENEATFQPKSNLFEVIKAVADDDTSIGVVPIENSIEGTINIVADALA..QQD

69
69
69
69
66
70
73
73
73
73
73
70
70
74
71

Bant
Bant
Bsub
Bsub
Bhal
Bhal
Linn
Linn
Lmon
Lmon
Efae
Efae
Llac
Llac
Spne
Spne
Atum
Atum
Rmel
Rmel
Bsui
Bsui
Mlot
Mlot
Bjap
Bjap
Rpal
Rpal
Mmag
Mmag
Magn
Magn
Ctep
Ctep
Drad
Drad
Ecol
Ecol
Styp
Styp
Eher
Eher
Hinf
Hinf
Vcho
Vcho
Paer
Paer
Pstu
Pstu
Tten
Tten
Saur
Saur

LSIVGEITVPIQQHLLVHPQYADVWEEVYAVHSHPHAIAQCHKFLNEELKGVTARDMTSTSAAAQYVKEHPEEKI
LPIVGEMTLPIHQHLLVHPSRENAWKELDKIYSHSHAIAQCHKFLHRHFPSVPYEYANSTGAAAKFVSDHPELNI
LEIVADIVVPISQHFLVHPNQRD..NEIKKILSHPHAVAQCHEFLRSSYPGVEIEYMTSTAAAAQWVADHPNEPV
VPVVAEIVLPIAQHLMVHPAHKATWKSVQKVMSHPQALAQCHTFLQAELYGVEREVTPSTAYAAKWVSNNPTELV
VPVVAEIVLPIAQHLMVHPAHVSAWKSVQKVMSHPQALAQCHTFLQAELYGVEREVTPSTAYAAKWVSNNPTELV
LPVQAELVLPIQQQLMVAKENQAIWQQSQKILSHPQALAQSQMFLEKNFPEAILEATPSTAYAAKYIAEHPELPF
ATVVAEFVLPISQNLLALSKE....GKIEHIYSHPQALAQTRNYLREHYPQAKVEITDSTSAAAEFVKNHPDLPI
IQAVAEIVQPIHQQLMVVPGH....TKIEKIFSHPQALAQGKKFIDEQYPEAQIEVTASTAYAARFISEHPDQPF
LHIIGEYFMPIRFQLMVVPGVTK..DEIRTVHSHIHALGQCRKIIRSN..GWKPVIAGDTAGSARLVSEKGDRSM
LHIVGEYFMPIRFQLMVLPGVGR..EEIRTVHSHIHALGQCRKIVRAN..GWKPVVAGDTAGAAKLVKEVGDRSM
MHIVGEYFLPIHFQLMVLPGVRR..EEIKTVHSHIHALGQCRNVIRQN..GWKGVIAGDTAGAARLVADVKDRSM
MHIVGEYFLPIHFQLMVLPGVKR..DEIKTVHSHIHALGQCRKYIRKN..GWKAVVAGDTAGAAKMISEVKDRTM
LFIIGEWFLPVRHQLMAVKGAKI..SDIKSVESHVHALGQCRRIIRKL..GIKPIVHADTAGSARDISERKDKTV
LFIVGEWFLPIRHQLVAVPGAKL..EDIKTVESHVHALGQCRRIIRKF..GLKPIVAGDTAGSARIIAERGDKTC
LHIIAEHFERISHHLLAVPGATL..ATIKSVKSHVHALGQCRNLIREL..GLKVIVGTDTAGAAAELAERQDPTM
LHIIGEYYLPVRHCLMAHQGVNV..ERIHTVYSHPQALAQCHSFIKRH..GWNRVAVYDTAGAAAALKEEHREGE
VVILAETFVKVEHCLLGLPGASV..ETATKAMSHPQALVQCHNFFATHP.QIRAEAAYDTAGSAKMVAESRDKSA
LHVTGEVVVRVSHCLMALPGVEM..ADIRKVGSQQPALDQCTHLIREH..GWQPLAKHDTAGSAKDLAERGARDE
LSIVGEMTLTIDHCLLVSGTTDL..SAINTVYSHPQPFQQCSKFLNRYP.HWKIEYTESTSAAMEKVAQAKSPHV
LSIVGEMTVTIDHCVLVSGATDL..NTIETVYSHPQPFQQCSKFLSRYP.HWKIDYTESTSAAMEKVAQANSPRV
LSIVGELTLPIDHCVLVNGPTDL..QQIETVYSHPQPFQQCSQFINRFP.HWKIEYTESTAAAMEKVAALNSPKV
LSLVGELAYPIKHCVLVNDKTDL..NQIDTLYSHPQVIQQCSQFIHSLD.RVHIEYCESSSHAMQLVASLNKPNI
LYIVGELTQPIEHCLVATQEIRL..EDLKVLYSHPQPHQQCSEFLSRLK.GVKLESCASTADAMKKVQELNRADV
MVICGEVELRIHHHLLVGETTKT..DNITRIYSHAQSLAQCRKWLDSH..YPSVERVAVSSNADAAKRVKSEWNS
IVICGEVELRIHHHLLVGETTKT..DRITRIYSHAQSLAQCRKWLDAH..YPNVERVAVSSNADAAKRVKSEWNS
ILVRGEVIISISQCLICDDFIDF..KDVHCILSHPQALAQCREYILNN..FPTAEVKTTESTVKALLGVNAKKGI
VFAHGEIRLDINFALYGNGTDSI..SDIKKVYSIAPAISQTTNYIHQH..QFDYDYVDSTIQSLTKIEN....GV

145
147
146
146
144
144
145
146
145
145
145
145
141
141
141
141
140
140
140
140
140
140
140
140
140
140
140
140
140
140
140
140
138
138
141
141
145
145
145
145
145
145
145
145
145
145
141
141
141
141
145
145
138
138

Bant
Bsub
Bhal
Linn
Lmon
Efae
Llac
Spne
Atum
Rmel

AAIANEAAAEKYGLTIVRRGIHTHKNNHTRFLVLHKKKKAILPNNGENRGE.KTTLMITLP.ADYAGALYQVLSA
GVIANDMAASTYELKIVKRDIQDYRDNHTRFVILSPDENISFEVNSKLSSRPKTTLMVMLPQDDQSGALHRVLSA
AAIANEQAATSYQLDMLEKDIHDYDENRTRFAVLAKGKLSLPPYQVEPYTK.KTTMMVTLS.SDFSGALHQVLSA
AAIAPRMAASEYGLEIVQENAQDLELNQTRFFVLSRKPVSILLPKEE...E.KTSISVILP.NNMPGALHKVLST
AAIAPRMAANEYGLEIVKENAQDLELNQTRFFVLSRKPVSILLPKEE...E.KTSISVILP.NNMPGALHKVLST
AAIAPKLSAEMYDLTIVEKNIQDLSVNQTRFWVLGSENLAISFPLSE...K.KITLAITMP.SNVPGSLHKVLSV
AAVANSYAAKMYDLEIVAKNIQDLAGNSTRFWLLGKEKKSFDLLKTG...E.KVSLALTLP.DNLPGALHKAISV
	
  
AAVAPRSSAEEYGLELIAEDIQEMEANFTRFWVLGAEKPSIPLQAQT...E.KMSLALTLP.DNLPGALYKALST
AALAPRLAADLYGLDILAENVEDSENNVTRFVVLSRDENWAKRQ....SSDEIVVTTFVFNVRNIPAALYKAMGG
AALAPRLAADLYGLDIIAENVEDTDSNVTRFVVLSREESRVART....SKDELIITTFVFNVRNIPAALYKAMGG

218
221
217
215
215
215
211
211
211
211
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Rpal
Mmag
Magn
Ctep
Drad
Ecol
Styp
Eher
Hinf
Vcho
Paer
Pstu
Tten
Saur

LFIVGEWFLPIRHQLVAVPGAKL..EDIKTVESHVHALGQCRRIIRKF..GLKPIVAGDTAGSARIIAERGDKTC
LHIIAEHFERISHHLLAVPGATL..ATIKSVKSHVHALGQCRNLIREL..GLKVIVGTDTAGAAAELAERQDPTM
LHIIGEYYLPVRHCLMAHQGVNV..ERIHTVYSHPQALAQCHSFIKRH..GWNRVAVYDTAGAAAALKEEHREGE
VVILAETFVKVEHCLLGLPGASV..ETATKAMSHPQALVQCHNFFATHP.QIRAEAAYDTAGSAKMVAESRDKSA
LHVTGEVVVRVSHCLMALPGVEM..ADIRKVGSQQPALDQCTHLIREH..GWQPLAKHDTAGSAKDLAERGARDE
LSIVGEMTLTIDHCLLVSGTTDL..SAINTVYSHPQPFQQCSKFLNRYP.HWKIEYTESTSAAMEKVAQAKSPHV
LSIVGEMTVTIDHCVLVSGATDL..NTIETVYSHPQPFQQCSKFLSRYP.HWKIDYTESTSAAMEKVAQANSPRV
LSIVGELTLPIDHCVLVNGPTDL..QQIETVYSHPQPFQQCSQFINRFP.HWKIEYTESTAAAMEKVAALNSPKV
LSLVGELAYPIKHCVLVNDKTDL..NQIDTLYSHPQVIQQCSQFIHSLD.RVHIEYCESSSHAMQLVASLNKPNI
LYIVGELTQPIEHCLVATQEIRL..EDLKVLYSHPQPHQQCSEFLSRLK.GVKLESCASTADAMKKVQELNRADV
MVICGEVELRIHHHLLVGETTKT..DNITRIYSHAQSLAQCRKWLDSH..YPSVERVAVSSNADAAKRVKSEWNS
IVICGEVELRIHHHLLVGETTKT..DRITRIYSHAQSLAQCRKWLDAH..YPNVERVAVSSNADAAKRVKSEWNS
ILVRGEVIISISQCLICDDFIDF..KDVHCILSHPQALAQCREYILNN..FPTAEVKTTESTVKALLGVNAKKGI
VFAHGEIRLDINFALYGNGTDSI..SDIKKVYSIAPAISQTTNYIHQH..QFDYDYVDSTIQSLTKIEN....GV

140
140
140
138
141
145
145
145
145
145
141
141
145
138

Bant
Bant
Bsub
Bsub
Bhal
Bhal
Linn
Linn
Lmon
Lmon
Efae
Efae
Llac
Llac
Spne
Spne
Atum
Atum
Rmel
Rmel
Bsui
Bsui
Mlot
Mlot
Bjap
Bjap
Rpal
Rpal
Mmag
Mmag
Magn
Magn
Ctep
Ctep
Drad
Drad
Ecol
Ecol
Styp
Styp
Eher
Eher
Hinf
Hinf
Vcho
Vcho
Paer
Paer
Pstu
Pstu
Tten
Tten
Saur
Saur

AAIANEAAAEKYGLTIVRRGIHTHKNNHTRFLVLHKKKKAILPNNGENRGE.KTTLMITLP.ADYAGALYQVLSA
GVIANDMAASTYELKIVKRDIQDYRDNHTRFVILSPDENISFEVNSKLSSRPKTTLMVMLPQDDQSGALHRVLSA
AAIANEQAATSYQLDMLEKDIHDYDENRTRFAVLAKGKLSLPPYQVEPYTK.KTTMMVTLS.SDFSGALHQVLSA
AAIAPRMAASEYGLEIVQENAQDLELNQTRFFVLSRKPVSILLPKEE...E.KTSISVILP.NNMPGALHKVLST
AAIAPRMAANEYGLEIVKENAQDLELNQTRFFVLSRKPVSILLPKEE...E.KTSISVILP.NNMPGALHKVLST
AAIAPKLSAEMYDLTIVEKNIQDLSVNQTRFWVLGSENLAISFPLSE...K.KITLAITMP.SNVPGSLHKVLSV
AAVANSYAAKMYDLEIVAKNIQDLAGNSTRFWLLGKEKKSFDLLKTG...E.KVSLALTLP.DNLPGALHKAISV
AAVAPRSSAEEYGLELIAEDIQEMEANFTRFWVLGAEKPSIPLQAQT...E.KMSLALTLP.DNLPGALYKALST
AALAPRLAADLYGLDILAENVEDSENNVTRFVVLSRDENWAKRQ....SSDEIVVTTFVFNVRNIPAALYKAMGG
AALAPRLAADLYGLDIIAENVEDTDSNVTRFVVLSREESRVART....SKDELIITTFVFNVRNIPAALYKAMGG
AALAPRLAADLYGLDILEENVEDSENNVTRFVVLSKNKQWAARP....ENDERIVTTFVFRVRNVPAALYKALGG
AALSPALAATLYGLDIIEENVEDTDSNVTRFVVLTKSKQWAERP....SPDVKMMTTFIFRVRNVPAALYKAMGG
AAIASRLAAKIYGLDILAEDIEDEAHNTTRFVVLAREPKWAAQG....SGP..LVTTFVFRVRNLPAALYKALGG
AAISSRLAAKIYGLDILAEDIEDEAHNTTRFVVLAREPRWAVQG....SGK..LVTTFVFRVRNLPAALYKALGG
AAIASELAAEAYGLVSLKAGIEDAEHNTTRFVVLAREA.LEPNP....NQP..CVTTFVFRVRNVAAALYKALGG
AAIASALAAELYGLDLLAEQIQDSANNTTRFLIIAKDG.IIPMP....NVG..CKISLLFEVRHIPAALYKCLGG
LAIASKRAGELYGLDILKENLADEEWNITRFFCIAHENNPDISHLKVRPDVARQKTSIVFALPNEQGSLFRALAT
AAIASRRAAELYGLNILQTGVEDEPFNFTRFMVLSR.HAP.......EPSDAPHKTSLIFAVRHTPGFLLETLG.
AALGSEAGGTLYGLQVLERIEANQRQNFTRFVVLARKAIN.......VSDQVPAKTTLLMATGQQAGALVEALLV
AALGSEAGGMLHGLQVLERIAANQTQNITRFLVLARKAIN.......VSDQVPAKTTLLIATGQQAGALVEALLV
AALGSEAGGELYQLQVLERNLANQQQNHTRFIVLARKAIE.......VSDQVPAKTTLIMATGQQAGALVDALLV
AALGNEDGGKLYGLSVLKTNIANQENNITRFIVVAKEPRE.......VSSQIPTKTLLLMTTSQQAGALVDALLV
AAIGNSASGKLYGLQPIQGNIANQTENHTRFIVVARKPVD.......VSPQIPAKTTLIMSTSQEAGSLVSTLLV
AAIAGDMAASLYDLSKLHEKIEDRPDNSTRFLIIGNQEVP.........PTGDDKTSIIVSMRNKPGALHELLVP
AAIAGDMAAQLYGLSKLAEKIEDRPVNSTRFLIIGSQEVP.........PTGDDKTSIIVSMRNKPGALHELLMP
VAIGPERAAWLYNLKILEKDVQDIKENYTRFLVIAKRDSD.........YTGEDKTSIVFSVPNVPGSLYRALGV
AAIAPLGSGEAYGFTPIDTHIEDYPHNVTRFLVIKNQQQFD........QNATSLMFLITPMHDKPGLLASVLNT

218
218
221
221
217
217
215
215
215
215
215
215
211
211
211
211
211
211
211
211
211
211
211
211
209
209
209
209
208
208
208
208
213
213
207
207
213
213
213
213
213
213
213
213
213
213
207
207
207
207
211
211
205
205

Bant
Bsub
Bhal
Linn
Lmon
Efae
Llac
Spne
Atum

FAWRKLNLSKIESRPMKTGLGNYFFLIDVDKAYDEV.LLPGVTMELEALGFSVTVLGSYSSYWL..........
FSWRNLNLSKIESRPTKTGLGHYFFIIDIEKAFDDV.LIPGAMQELEALGCKVRLLGAYQSYQL..........
FAWRKLNLTKIESRPMKTGLGNYFFIIDVDCEADDV.LIPGVMQELEALGCGVELLGSYPCFFHTSLKLTEASS
FAWRDIDLSKIESRPLKTSLGEYFFLIDVLSEGKET.LVTNALDEIRLLGGKANKLGTYHVHRLQTT.......
FAWRDIDLSKIESRPLKTSLGEYFFLIDVLSEGKEV.LVTNALDEITLLGGTANKLGTYHVHRLQTN.......
FSWRGINLSKIESRPLKTKLGEYFFLMDLVKDQPEK.LIEAALTELELIGAEIKILGDYPIYVLSTL.......
	
  
FAWRDIDMTKIESRPLRTRLGQYFFNIDLVNNEKNNLKIPYALEELSGLGVKVRLLGNYAVYSLGEG.......
FAWRGIDLTKIESRPLKTALGEYFFIIDVDYTDKD..LVHFAQKELEAIGIQYKILGAYPIYPISDHGKERR..
FATNGINMTKLESYQLGGKFVATQFYADIEGHPDDE.PVRHALDELRFFSEKVRILGVYNGHAMRGKLNQS...

281
284
290
281
281
281
278
281
281
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Mmag
Magn
Ctep
Drad
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Eher
Hinf
Vcho
Paer
Pstu
Tten
Saur
Bant
Bant
Bsub
Bsub
Bhal
Bhal
Linn
Linn
Lmon
Lmon
Efae
Efae
Llac
Llac
Spne
Spne
Atum
Atum
Rmel
Rmel
Bsui
Bsui
Mlot
Mlot
Bjap
Bjap
Rpal
Rpal
Mmag
Mmag
Magn
Magn
Ctep
Ctep
Drad
Drad
Ecol
Ecol
Styp
Styp
Eher
Eher
Hinf
Hinf
Vcho
Vcho
Paer
Paer
Pstu
Pstu
Tten
Tten
Saur
Saur

AAIASELAAEAYGLVSLKAGIEDAEHNTTRFVVLAREA.LEPNP....NQP..CVTTFVFRVRNVAAALYKALGG
AAIASALAAELYGLDLLAEQIQDSANNTTRFLIIAKDG.IIPMP....NVG..CKISLLFEVRHIPAALYKCLGG
LAIASKRAGELYGLDILKENLADEEWNITRFFCIAHENNPDISHLKVRPDVARQKTSIVFALPNEQGSLFRALAT
AAIASRRAAELYGLNILQTGVEDEPFNFTRFMVLSR.HAP.......EPSDAPHKTSLIFAVRHTPGFLLETLG.
AALGSEAGGTLYGLQVLERIEANQRQNFTRFVVLARKAIN.......VSDQVPAKTTLLMATGQQAGALVEALLV
AALGSEAGGMLHGLQVLERIAANQTQNITRFLVLARKAIN.......VSDQVPAKTTLLIATGQQAGALVEALLV
AALGSEAGGELYQLQVLERNLANQQQNHTRFIVLARKAIE.......VSDQVPAKTTLIMATGQQAGALVDALLV
AALGNEDGGKLYGLSVLKTNIANQENNITRFIVVAKEPRE.......VSSQIPTKTLLLMTTSQQAGALVDALLV
AAIGNSASGKLYGLQPIQGNIANQTENHTRFIVVARKPVD.......VSPQIPAKTTLIMSTSQEAGSLVSTLLV
AAIAGDMAASLYDLSKLHEKIEDRPDNSTRFLIIGNQEVP.........PTGDDKTSIIVSMRNKPGALHELLVP
AAIAGDMAAQLYGLSKLAEKIEDRPVNSTRFLIIGSQEVP.........PTGDDKTSIIVSMRNKPGALHELLMP
VAIGPERAAWLYNLKILEKDVQDIKENYTRFLVIAKRDSD.........YTGEDKTSIVFSVPNVPGSLYRALGV
AAIAPLGSGEAYGFTPIDTHIEDYPHNVTRFLVIKNQQQFD........QNATSLMFLITPMHDKPGLLASVLNT

208
208
213
207
213
213
213
213
213
207
207
211
205

FAWRKLNLSKIESRPMKTGLGNYFFLIDVDKAYDEV.LLPGVTMELEALGFSVTVLGSYSSYWL..........
FSWRNLNLSKIESRPTKTGLGHYFFIIDIEKAFDDV.LIPGAMQELEALGCKVRLLGAYQSYQL..........
FAWRKLNLTKIESRPMKTGLGNYFFIIDVDCEADDV.LIPGVMQELEALGCGVELLGSYPCFFHTSLKLTEASS
FAWRDIDLSKIESRPLKTSLGEYFFLIDVLSEGKET.LVTNALDEIRLLGGKANKLGTYHVHRLQTT.......
FAWRDIDLSKIESRPLKTSLGEYFFLIDVLSEGKEV.LVTNALDEITLLGGTANKLGTYHVHRLQTN.......
FSWRGINLSKIESRPLKTKLGEYFFLMDLVKDQPEK.LIEAALTELELIGAEIKILGDYPIYVLSTL.......
FAWRDIDMTKIESRPLRTRLGQYFFNIDLVNNEKNNLKIPYALEELSGLGVKVRLLGNYAVYSLGEG.......
FAWRGIDLTKIESRPLKTALGEYFFIIDVDYTDKD..LVHFAQKELEAIGIQYKILGAYPIYPISDHGKERR..
FATNGINMTKLESYQLGGKFVATQFYADIEGHPDDE.PVRHALDELRFFSEKVRILGVYNGHAMRGKLNQS...
FATNGINMTKLESYQLGGKFVATQFYADIEGHPDDI.GVRHAMDELRFFSENVRILGTYPAHPMRGVL......
FATNGVNMTKLESYQLGGRFIATQFYADIEGHPEER.SVQLALEELRFFTKEVRILGVYKGSDIRGTQLLAAE.
FATNGINMTKLESYQLG.AFTATLFYADIEGHPDDP.LVKLALDELRFFSREVRILGVYPASESR.EQWKVAD.
FATNGVNMTKLESYMVDGNFFATQFYADVDGHPEDK.GLAFAIEELKFFSREFRIVGVYPGHPFRATFSETQQD
FATNGVNMTKLESYMVDGNFFATQFYADVEGHPEDR.NLAFALDELKFFSREFRIVGVYPGHPFRATFSER...
FATNGINMTRLESYMVGGEFAATQFYADVEGHPTQR.NLRLALEELDFFSHEVRILGVYPRHPFRMKQQGGGQ.
FATNGINLTRLESRPVAGRDWSYHFYLDFQGRMDQV.NVQQALEELKFYTHNMKVLGCYP.ESLRPESQGAL..
FALRGIDLTKIESRPSRKKAFEYLFYADFIGHREDQ.NVHNALENLREFATMVKVLGSYGVVNP..........
.ELRGLNLSRIESRPRRDRAWSYLMYVDIEGKASDP.QVAQALAGILVKASYAKIIGSYPAAQGTVQ.......
LRNHSLIMTRLESRPIHGNPWEEMFYLDIQANLESA.EMQKALKELGEITRSMKVLGCYPSENVVPVDPT....
LRNHNLIMTKLESRPIHGNPWEEMFYLDIQANLESQ.VMQSALKELGEITRSMKVLGCYPSENVVPVEPA....
LRQHNLIMSKLESRPINGNPWEEMFYIDVQGNLQSE.RMQQALQELQTMTRSLKVLGCYPSENVVPAEPGR...
FKKHQINMTKLESRPIYGKPWEEMFYLEIEANIHHP.DTKQALEELKNYSNYLKILGCYPSEIVKPVSV.....
LQRYGINMTKLESRPIMGNPWEEMFYVDLEAHIDSD.EMQQALAELTQLTRHLKVLGCYPSENVKPTQVKFI..
FHNNGIDLTRIETRPSRSGKWTYVFFIDFVGHHKEP.LIKDVLEKIGQEAVALKVLGSYPKAVL..........
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Next, the six Arabidopsis ADT protein sequences were aligned. These
sequences were aligned separately from the bacterial PDT sequences because
the diverse PDT sequences disrupted the ADT alignment and made analysis
difficult. The goal of the ADT alignment was to identify amino acid sites that may
be responsible for the distinction between an ADT that can accept both
arogenate and prephenate (ADT1 and ADT2) and a solely arogenate-accepting
ADT (ADT3 – ADT6). To investigate this, an amino acid site was highlighted if it
fulfilled three criteria:
1. There was a conserved amino acid between ADT1 and ADT2.
2. There was a conserved amino acid between ADT3-ADT6.
3. These two amino acids were different.
The 18 amino acid sites that met these requirements are highlighted in
yellow in Figure 15.
Then, the results from the PDT alignment and the ADT alignment were
compared. First, the 40 amino acids conserved in the bacterial PDTs were
located in the ADT alignment. The goal of this comparison was to identify amino
acids that were common between the bacterial PDTs and ADT1 and ADT2 but
different from ADT3 – ADT6. However, all 40 of these amino acids that were
conserved among the bacterial PDTs are present in both the ADT1/ADT2 and
ADT3 – ADT6 groups. In most cases, these amino acids were present in all six of
the Arabidopsis ADTs. These sites are highlighted in blue in Figure 15. Since
they are found in both of the ADT groups, it is unlikely that these amino acids can
distinguish between a prephenate-accepting and a solely arogenate-accepting
ADT.
In an alternative approach, the 18 amino acid sites that were identified in
the ADT alignment were located in the PDT alignment. Again, the goal of this
comparison was to identify amino acid sites that were common between the
bacterial PDT sequences and ADT1 and ADT2, but different from the amino acid
in ADT3 – ADT6 at the same site. Due to the high level of diversity in the
bacterial PDT sequences, only 16 of the 18 amino acid sites could be identified
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Figure 15. Protein sequence alignment of Arabidopsis ADTs.
Partial alignment of the 6 ADT protein sequences from Arabidopsis thaliana
generated with DNAMAN. The transit peptide sequences have been removed.
Blue highlight: 40 amino acid locations that were identified in the bacterial PDTs
as similar in more than 75% of the PDT sequences; yellow highlight: the 18
amino acid sites identified in the ADTs that differed between ADT1/ADT2 and
ADT3 – ADT6; star: the 10 amino acid sites identified in the ADT alignment that
contained both the amino acid from ADT1/ADT2 and the amino acid from ADT3 –
ADT6 in the PDT sequences; question mark: the two amino acid sites identified
in the ADTs that differed between ADT1/ADT2 and ADT3 – ADT6 that could not
be found in the PDT sequences; arrow: the 6 amino acid sites identified in the
ADT alignment that did not contain the amino acid found in ADT3 – ADT6 in the
PDT sequences; green arrow: the amino acid position that corresponds to the
Phe341Leu substitution in ADT5 (discussed in section 3.5).
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with certainty. The two sites that could not be identified are labeled with a
question mark in Figure 15 and the 16 amino acid sites that could be identified
are highlighted in yellow in Figure 14. Of these 16 sites, 10 had the amino acid in
ADT1/ADT2 as well as the amino acid found in ADT3 – ADT6 (stars in Figure
14). Therefore, these 10 amino acids were unlikely to be important for
differentiating between a prephenate-accepting ADT and a solely arogenateaccepting ADT. The remaining 6 sites, however, did not contain the amino acid
found in ADT3 – ADT6, which indicated that these amino acids might be
important for ADT vs. PDT distinction (arrows in Figure 14).
As a third approach, an alignment of CDT protein sequences was
analyzed. This was done because these enzymes can accept both arogenate
and prephenate as substrates, and the comparison of their sequences with the
ADTs and PDTs might reveal which amino acids are important for prephenate
recognition. The CDT sequences were obtained from Burkholderia pseudomallei
(YP_109985.1),

Acidovorax

(YP_003967695.1),

citrulli

(ABM33045.1),

Bradyrhizombium

diazoefficiens

Ilyobacter

polytropus

(NP_771201.1),

and

Pseudomonas aeruginosa (CDH69854.1). However, the CDTs were found to be
too distinct from both the plant ADT and bacterial PDT protein sequences to
provide any valuable information (data not shown).
Therefore, the number of amino acid sites that might be important for
distinguishing between a prephenate-accepting ADT and a solely arogenateaccepting ADT could not be narrowed down any further. Six is a large number of
sites to target for testing protein function, particularly if a combination of several
of these sites is required for prephenate recognition. Therefore, it was concluded
that it was not practical to determine the amino acid(s) that are responsible for
this distinction through specifically targeting these 6 amino acids.

3.2 Random mutagenesis
The results of the in silico analysis indicated that it was not practical to use
targeted codon mutagenesis to determine which amino acids are required for

	
  

	
   75	
  
distinguishing between a prephenate-accepting ADT and a solely arogenateaccepting ADT. Therefore, it was decided to use another approach.
First, a random mutagenesis method was tried. One advantage of random
mutagenesis is that it is an unbiased method that does not require any
knowledge regarding putative sites of interest in the sequence to be mutated. A
second advantage of this method is that it has the capacity to generate a large
library of mutants that can be screened for changes in function caused by the
mutation(s). The goal of this method was to randomly mutate an arogenatespecific ADT through error-prone PCR to introduce PDT function to the enzyme.
Therefore, full-length ADT4 and ADT6 cDNA sequences (both solely arogenateaccepting; Cho et al. 2007) were selected for random mutagenesis. The ADT4
and ADT6 cDNA libraries were generated and transformed into pha2, the PDTknockout yeast strain, to test for mutants that had acquired PDT function.
However, it was difficult to generate a sufficient number of transformants. Only
2000 transformants were successfully generated. A subset of each library was
sequenced, and approximately 15% of the sequences were identified as wild
type. That means that of the 2000 transformants only approximately 1700 (85%)
would be useful for the PDT screen. Many more transformants would need to be
generated in order to exhaustively screen the libraries (Appendix A) and
therefore it was concluded that the random mutation method would not be
pursued any further.
3.3 Domain swapping
In a second approach it was decided to identify the domain (TP, catalytic, or
ACT) that can distinguish between a prephenate-accepting ADT and a solely
arogenate-accepting ADT. For this, a domain from a prephenate-accepting ADT
was swapped with a domain from a solely arogenate-accepting ADT and the
resulting “chimera” was tested for PDT function in a pha2 yeast complementation
assay. If the chimera is able to complement the PDT knockout pha2 yeast strain,
this indicates that the domain from the prephenate-accepting ADT contains
sequences for prephenate recognition. ADT2 and ADT4 were initially chosen for
this research. ADT2 was chosen for domain swapping because it displayed the
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highest level of prephenate recognition of the six ADTs in biochemical analyses
(240 M-1s-1; Cho et al. 2007). ADT4 was chosen because it had been previously
studied by other members of the lab (White 2011; Karademir 2012), and has
been identified as solely arogenate-accepting both in vitro and in vivo (Cho et al.
2007; Bross et al. 2011).
3.3.1 Generating ADT2/ADT4 chimeras
Overlap extension PCR was used to assemble the ADTs with swapped
domains (Figure 9). In this method, two fragments are independently amplified
from two different templates (Figure 9A). The 5’ fragment is amplified with a 5’
gene specific primer and a 3’ primer that incorporates 15-24 bp of the other
template. Conversely, the 3’ fragment is amplified with a 3’ gene specific primer
and a 5’ primer that incorporates 15-24 bp of the first template. Then, the two
fragments are both used as templates in a third PCR reaction (Figure 9B) in
which the overlapping sequences facilitate the annealing of the two fragments
and can act as an extension starting point to generate the full-length chimera.
Only the outer primers are used for this third PCR reaction.
A schematic for the six full-length ADT2/ADT4 chimeras that were generated
through overlap extension PCR is outlined in Figure 10. These chimeras were
designed to contain every possible combination of the three domains from ADT2
and ADT4. All initial PCR fragments generated are listed in Table 7 together with
their expected length. PCR fragments were analyzed by gel electrophoresis to
ensure that they were of appropriate length (Figure 16A).
The fragments were then used in combination as templates for the overlap
extension PCR to generate the full-length chimeras. Expected sizes are given in
Table 7 and the corresponding electrophoresis results are shown in Figure 16B.
After PCR amplification, the ADT chimera sequences were recombined into
the donor vector. This recombination was facilitated by the att recombination
sites that were integrated onto the 5’ and 3’ ends of the constructs by the outer
Gateway® Recombination primers (Table 3; Figure 8). All inserts were
sequenced and only inserts that contained the correct combination of domains
and lacked PCR amplification errors were chosen. The chosen inserts were then
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Figure 16. ADT2/ADT4 chimeras.
(A) Agarose gels of ADT2 and ADT4 fragments containing the 15-24 bp of
overlapping sequences. These fragments were used as templates in the overlap
extension PCR to produce Chimera 1 – Chimera 6. (B) Agarose gel of Chimera 1
– Chimera 6.
L: 1 Kb ladder. All gels are 1% agarose and all sizes are in Kb.
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recombined into the yeast compatible pAG423GAL-ccdB-ECFP destination
vector.
3.3.2 Complementation assay of ADT2/ADT4 chimeras
To determine if Chimera 1 – Chimera 6 have PDT activity in vivo, they
were transformed into the pha2 yeast strain for the complementation assay. Fulllength ADT2 was used as a positive control and full-length ADT4 was used as a
negative control. In addition, yeast transformed with an empty destination vector,
and untransformed yeast cells were used as negative controls.
Yeast cells were grown for 24 hours in appropriately supplemented liquid
SD media containing raffinose. Raffinose media was chosen as it neither inhibits
nor induces expression from the GAL1 promoter in the destination vector
(Weinhandl et al. 2014). The cells were spotted onto solid SD media plates
supplemented as described previously (section 2.8). To ensure the reproducibility
of the complementation results, two samples of yeast cells that were
independently transformed with the same chimera were each spotted twice.
Every complementation assay was repeated three times. The results for all
replicates and repeats were identical. Therefore, a single set of representative
data is shown.
Differential growth in the yeast samples was observed by day 13.
Therefore, only data from this day is shown in Figure 17. By this day, the yeast
transformed with ADT constructs were able to grow on media supplemented with
Phe, regardless of the carbon source used. The pha2 strain was unable to grow
on any media as it is untransformed and contains no vector. Yeast transformed
with an empty destination vector was able to grow on all media as long as it was
supplemented with Phe. All yeast samples containing an ADT construct were
unable to grow on glucose or raffinose media if it lacked Phe. As demonstrated
previously (Bross 2011), ADT2 was able to grow on inducing selective media
lacking Phe whereas ADT4 did not. These controls indicate that all yeast
samples have the ability to grow on all carbon sources if fully supplemented, that
the GAL1 promoter is only induced on media containing
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Figure 17. Complementation of the pha2 phenotype for ADT2/ADT4
chimeras.
Growth of pha2 yeast samples for the ADT2/ADT4 complementation assay on
day 13. On the left, diagrams for the full-length chimeric sequences are shown.
ADT2 domains are shown in white and ADT4 domains are shown in purple. The
samples were spotted at a cell density of 1 x 105 cells/mL on selective solid SD
media containing glucose, raffinose or galactose. For each of these carbon
sources, the samples were spotted on media containing Phe and media lacking
Phe.
pha2: un-transformed pha2 yeast; pDEST: yeast transformed with the empty
destination vector; Glu: Glucose; Raf: raffinose; Gal: galactose; +Phe: media
containing Phe; -Phe: media lacking Phe.
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galactose, and only an ADT with PDT function is able to grow on inducing
medium lacking Phe.
Yeast expressing Chimera 1, Chimera 3 and Chimera 5 were unable to
grow on galactose media lacking Phe. However, growth was observed for yeast
transformed with Chimera 2, Chimera 4 and Chimera 6 (Figure 17). The ability of
these chimeras to complement the PDT knockout pha2 phenotype indicates that
they can act as PDTs. The only ADT domain common to these three chimeras
was the ACT regulatory domain from ADT2. Therefore, it was concluded that the
ACT regulatory domain contains the sequences that can confer PDT function to
an arogenate-only ADT in vivo.

3.4 Functional analysis of ADT2 and ADT5
To confirm that the ACT domain is able to confer PDT activity to an
arogenate-only ADT, seven constructs with swapped domains were generated
using ADT2 and ADT5 as templates. Again, ADT2 was chosen for its ability to
complement the PDT knockout yeast phenotype (Bross et al. 2011). ADT5 was
chosen, like ADT4, because it is a solely arogenate-accepting ADT (Cho et al.
2007; Bross et al. 2011).
A schematic for the seven full-length ADT2/ADT5 chimeras that were
generated through overlap extension PCR is shown in Figure 11. Chimera 7 –
Chimera 10 are analogs to Chimera 1 – Chimera 4, respectively, to test if the
ADT2 ACT domain confers PDT activity to the ADT5 sequence. Three additional
chimeras (Chimera 11 – Chimera 13) were created to narrow down whether it
was the N-terminal half, the C-terminal half, or the catalytic:ACT domain border
of the ACT domain that contains the sequences that can confer PDT to an
arogenate-only ADT. The construct borders for Chimera 11 – Chimera 13 are
shown in the ADT protein sequence alignment in Figure 18.
Primers were designed as described previously (Table 3; section 3.3.1),
fragments and chimeras (Table 8) were amplified by PCR and overlap extension
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Figure 18. Construct design for the N-terminal ACT domain.
Protein sequence alignment of partial catalytic and ACT domains of the six
Arabidopsis ADTs generated with DNAMAN. Dark blue: C-terminal catalytic
domain sequences; light green: N-terminal ACT domain sequences; dark green:
C-terminal ACT domain sequences; black lines: the borders of Chimera 11 –
Chimera 13. Amino acid sites that were identified as different for ADT1 and ADT2
vs. ADT3 – ADT6 are indicated in red. The SLEEG group was swapped between
ADT2 and ADT5. All amino acid locations listed correspond to the location in the
ADT5 protein sequence, with the exception of 4-V396L which corresponds to this
location in the ADT4 sequence.
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PCR and the resulting PCR fragments were checked for the proper sizes by gel
electrophoresis (Figure 19A and 19B).
Chimera 7 – Chimera 13 were transformed into pha2 and were tested for
PDT activity using the complementation assay previously described (section
3.3.3). The same positive and negative controls were used with the exception
that full-length ADT5 replaced ADT4 as a negative control (Figure 20).
Differential growth was observed by day 11 and therefore images of yeast growth
on this day are presented in Figure 20. Chimera 7, Chimera 9 and Chimera 11
were unable to support yeast growth on inducing medium lacking Phe. However,
Chimera 8 and Chimera 10, Chimera 12, and Chimera 13 were able to support
yeast growth on this media. The only region that was common between these
chimeras was the N-terminal half of the ACT domain from ADT2.
Therefore, it was concluded that this region contains the sequences for
the PDT activity of ADT2 and can confer PDT function to ADT5 in vivo. This area
is defined by 38 amino acids that span from Phe286 to Leu323 in ADT2 (Figure
18).

3.5 in silico analysis of the N-terminal ACT domain
To identify the exact amino acids in the N-terminal ACT domain that can
confer PDT function to an arogenate-only ADT, the protein sequence alignments
were revisited. The purpose of this in silico analysis was to identify amino acid
sites that were common between the bacterial PDT sequences and ADT1 and
ADT2, but different from the amino acid in ADT3 – ADT6. Two sites fulfilled these
criteria, the positions of which are indicated in Figure 18. At the first site, which
corresponds to Phe341 in ADT5, ADT1 and ADT2 have a leucine (Leu) and
ADT3 – ADT6 have a Phe. This position was substituted from a Phe to a Leu in
the ADT5 sequence (5-F341L; Figure 12). At the second site, which corresponds
to Ser345 in ADT5, ADT1 and ADT2 contain an asparagine (Asn) and ADT3 –
ADT6 contain a serine (Ser). This position was substituted from a Ser to an Asn
in ADT5 (5-S345N; Figure 12). A double
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Figure 19. ADT2/ADT5 chimeras.
(A) Agarose gels of ADT2 and ADT5 fragments containing the 15-24 bp of
overlapping sequences. These fragments were used as templates in the overlap
extension PCR to produce Chimera 7 – Chimera 13. (B) Agarose gel of Chimera
7 – Chimera 13.
L: 1 Kb ladder. All gels are 1% agarose and all sizes are in Kb.
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Figure 20. Complementation of the pha2 phenotype for ADT2/ADT5
chimeras.
Growth of pha2 yeast samples for the ADT2/ADT5 complementation assay on
day 11. On the left, diagrams for the full-length chimeric sequences are shown.
ADT2 domains are shown in white and ADT5 domains are shown in green. The
samples were spotted at a cell density of 1 x 105 cells/mL on selective solid SD
media containing glucose, raffinose or galactose. For each of these carbon
sources, the samples were spotted on media containing Phe and media lacking
Phe.
pha2: un-transformed pha2 yeast; pDEST: yeast transformed with the empty
destination vector; Glu: Glucose; Raf: raffinose; Gal: galactose; +Phe: media
containing

Phe;

-Phe:

media
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mutant was also generated that substituted both of these amino acids in ADT5
(5-DM; Figure 12).
In addition, a group of amino acids upstream of these two sites differs
between ADT1/ADT2 and ADT3 – ADT6 (Figure 18). The amino acids
corresponding to this group in the bacterial PDTs more closely resembled the
group in ADT1/ADT2 than ADT3 – ADT6. This group will be referred to as the
SLEEG group, due to the N-SLEEG-C motif observed in this group in ADT1 and
ADT2. This region was swapped between ADT2 and ADT5 and two constructs
were designed: 5-SLEEG and 2-SLEEG. 5-SLEEG contained ADT5 sequences
from the N-terminus of the transit peptide to the last amino acid of the SLEEG
region (S331) and ADT2 sequences from the corresponding ADT2 site (G299) to
the C-terminus of the ACT domain. 2-SLEEG contained the reciprocal of this.
For comparison, an amino acid site that differed between ADT1/ADT2 and
ADT3 – ADT6, but was located in the C-terminal ACT domain, was chosen as a
negative control. This site corresponds to L263 in ADT2, V396 in ADT4, and
V397 in ADT5 (section 3.1; Figure 18) and was substituted for the ADT2 amino
acid in ADT4 and ADT5.

3.6 Functional analysis of sequences within the N-terminal ACT domain
A schematic for the seven full-length ADT chimeras that were generated
through overlap extension PCR is outlined in Figure 12.
Primer design, fragment amplification and overlap extension PCR were
performed as previously described (section 3.3.1) to generate the new
constructs. For the generation of the point mutations, the primers contained
nucleotide changes causing amino acid substitutions (Table 4). Primers for the
amplification of 5-F341L contain a T>C substitution at nucleotide 1021, primers
for 5-S345N contain G>A1034, primers for 5-DM contain both of these mutations,
primers for 5-V397L contain G>T1189 and primers for 4-V396L contain
G>C1186.
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Fragments were amplified as previously described (section 3.3.1) and
analyzed with gel electrophoresis to check for the proper sizes (Figure 21A;
Table 9). The fragments were used as templates to generate the full-length
chimeras through overlap extension PCR as previously described (section 3.3.1)
with the exception of 5-SLEEG and 5-F341L. These chimeras could not be
successfully amplified using the standard thermocycler program and thus were
generated using the modified program described in Table 6. In this modified
program, the primers were added to the reaction after 10 cycles at an annealing
temperature of 55°C. This was done to ensure that amplification would only occur
once the fragments had annealed. Then, the polymerase would extend from the
overlapping sequences, generating the full-length chimeras. The full-length
products are then used as a template in the remaining cycles after the outer
primers are added. All chimeras were analyzed by gel electrophoresis to ensure
that they were of appropriate length (Figure 21B; Table 9).
The chimeras were tested then for PDT function in a complementation
assay as previously described (section 3.3.3), with the exception that both fulllength ADT4 and ADT5 were used as negative controls.
Differential growth of the chimeras was observed by day 13 and therefore
images of yeast growth on this date are presented in Figure 22. 5-SLEEG was
unable to grow on fully supplemented SD media. Therefore, it was concluded
that this chimera was unsuccessfully transformed into the pha2 yeast strain and it
was not considered for further study. 2-SLEEG, 5-S345N, 5-V397L, and 4-V396L
were unable to support growth on inducing medium lacking Phe. However, 5F341L and 5-DM were both able to complement the PDT knockout phenotype on
this medium. The only substitution that these two chimeras have in common is
the Phe341Leu substitution, in which a Phe was substituted for a Leu at amino
acid position 341 in ADT5. Therefore, it was concluded that the substitution of a
Leu for Phe at amino acid position 341 in ADT5 can result in the introduction of
PDT function to this arogenate-only ADT.
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Figure 21. N-terminal ACT domain chimeras.
(A) Agarose gels of ACT domain fragments containing the 15-24 bp of
overlapping sequences. These fragments were used as templates in the overlap
extension PCR to produce 5-F341L, 5-S345N, 5-DM, 5-SLEEG, 2-SLEEG, 4V396L and 5-V397L. (B) Agarose gel of 5-F341L, 5-S345N, 5-DM, 5-SLEEG, 2SLEEG, 4-V396L and 5-V397L chimeras.
L: 1 Kb ladder. All gels are 1% agarose and all sizes are in Kb.
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Figure 22. Complementation of the pha2 phenotype for N-terminal ACT
domain chimeras.
Growth of pha2 yeast samples for the N-terminal ACT domain complementation
assay on day 13. On the left, diagrams for the full-length chimeric sequences are
shown. ADT2 domains are shown in white, ADT4 domains are shown in purple,
and ADT5 domains are shown in green. The samples were spotted at a cell
density of 1 x 105 cells/mL on selective solid SD media containing glucose,
raffinose or galactose. For each of these carbon sources, the samples were
spotted on media containing Phe and media lacking Phe.
pha2: un-transformed pha2 yeast; pDEST: yeast transformed with the empty
destination vector; Glu: Glucose; Raf: raffinose; Gal: galactose; +Phe: media
containing Phe; -Phe: media lacking Phe.
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3.7 Protein induction and expression in pha2 Saccharomyces cerevisiae
Many of the ADT chimeras were unable to support growth of the pha2
yeast strain. It was important to ensure that the chimeras were expressed under
inducing conditions, otherwise the lack of yeast growth could be due to an
inability of the yeast to express the chimeras instead of a lack of PDT activity.
Total soluble protein (TSP) was extracted from pha2 yeast cells that
contained a single ADT protein and grown in liquid inducing media and a western
blot was performed as previously described (section 2.7; Figure 23). Equal
protein concentrations were size separated on an SDS PAGE gel, transferred
onto a nitrocellulose membrane and used for the western blot.
As all of the ADT proteins are ECFP fusion proteins, they were probed
with an anti-GFP antibody. Anti-GFP was used because ECFP and GFP are
similar enough that this antibody can detect both proteins. A GFP standard was
also loaded as a positive control to ensure that the anti-GFP antibody could bind
to GFP. Yeast transformed with full-length ADT2, ADT4 and ADT5 were
analyzed as positive controls. Yeast transformed with Chimera 11 and grown in
non-inducing conditions (“non-induced yeast”), yeast transformed with an empty
destination vector, and untransformed yeast were analyzed as negative controls.
ECFP was seen in all of the positive controls, but it was not detected in
the negative controls. A band of approximately 27 kDA was detected in the yeast
transformed with an empty destination vector (“pDEST” in Figure 23), which
corresponds to the 27.7 kDa size of the ECFP fusion protein, confirming that
ECFP can be detected with the GFP antibody.
ECFP was detected for all of the ADT-ECFP fusion proteins with the
exception of 5-SLEEG (Figure 23), which was considered to be untransformed.
For all samples, the top band corresponds to the expected size of the chimera
protein (Table 9) with the fusion protein attached. In addition, a band that is
approximately 10 kDa smaller was seen in yeast samples that were transformed
with Chimeras 2, 3, 7, 5-V397L, and full-length ADT5. Ten kDa corresponds to
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Figure 23. Expression of ADT constructs in pha2 yeast.
Western blots of all ADT constructs. Total soluble protein was isolated and
quantified using a BCA assay, 15 µg of total soluble protein was size separated
on 10% SDS-PAGE and Western blots were exposed for 1 min. (A) Western blot
containing ADT2/ADT4, ADT2/ADT5, and C-terminal ACT domain amino acid
substitution constructs and positive and negative controls. The concentration of
the GFP standard (lane 1) in this blot is 150 ng/µL. Due to the high signal
observed for this standard this concentration was decreased in (B). (B) Western
blot containing the N-terminal ADT2/ADT5 chimeras and ADT5 mutants, and fulllength ADT2 and ADT5. The GFP standard concentration in this blot in 75 ng/µL.
GFP: GFP standard; pha2: empty pha2 yeast; pDEST: yeast transformed with
the empty pAG423GAL-ccdB-ECFP; N: yeast transformed with Chimera 11 but
grown under non-inducing conditions (glucose). All sizes are in kDa.
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the approximate size of the transit peptide. This indicates that the transit peptide
is cleaved in these samples, and the smaller band represents the cleavage
product that lacks the transit peptide. ADT-ECFP fusion proteins without the
transit peptide can still be detected by the GFP antibody because the ECFP tag
is at the C-terminus of the protein. In addition, a small band corresponding to the
size of the transit peptide was also detected in yeast transformed with Chimeras
3, 5, 6, 7, 8, 12, 5-V397L and full-length ADT5. This indicates that the ECFP is
cleaved in these samples.
In conclusion, all of the ADT-ECFP fusion proteins (with the exception of
5-SLEEG) can be detected and hence are translated by the pha2 yeast.
Therefore, the lack of growth that was seen in many of these samples in the
complementation assay is due to a lack of PDT activity and not an inability of the
yeast to express the protein.

3.8 3D Homology modeling of the ACT domain
The results of the pha2 complementation assays indicate that a Phe to
Leu substitution at amino acid position 341 in ADT5 was able to confer PDT
activity to this enzyme. It is possible that the change in substrate specificity
observed in this altered ADT is due to a conformational change that is caused by
the Phe341Leu substitution. There is no structural information available for any of
the plant ADTs, which makes it difficult to confirm this prediction. However, there
are computer programs that can predict a protein’s structure by modeling its
sequence against that of a related protein with a known structure, using it as a
structural template. Based on the template’s structural information, this “3D
homology modeling” can predict what the overall conformation of the
uncharacterized protein will look like. For this study, a program named UCSF
Chimera was used to homology model the structure of ADT2 and ADT5. The
goal of this modeling was to predict whether the Phe341Leu substitution in ADT5
has an impact on its surrounding amino acids or the ADT5 overall conformation,
therefore altering the substrate specificity of this enzyme. The amino acid
position in ADT2 that corresponds to this substitution is Leu317. It was expected

	
  

100	
  
	
  
that the Phe341Leu substitution’s interactions with its surrounding residues
would more closely resemble those of the Leu317 in ADT2 than the Phe341 in
ADT5. In addition, it was expected that this substitution would alter the ADT5
overall structure to make it more similar to ADT2, a prephenate-accepting ADT.
First, the structure of ADT2 was predicted. To do this, a protein template
with a known crystal structure had to be chosen. A BLAST search was performed
to determine the most similar amino acid sequence for which there was a crystal
structure available in the Protein Data Bank (PDB). The PDT protein from C.
tepidum (Ct-PDT; QMXW) had the highest similarity to the ADT2 sequence. CtPDT, as described in section 1.6, is a homodimer. However, only a single chain
or subunit can be modeled at a time with the UCSF Chimera program (Figure
24A). Therefore, the ADT2 sequence was modeled after the Ct-PDT monomer.
The location of Leu317 was identified in the homology modeled ADT2 structure.
The location of Leu317 in ADT2 was predicted to be in an α-helix in the ACT
domain (Figure 24B). This correlates with the ACT dimer interface in Ct-PDT,
and the site of Phe ligand binding. Then, the “FindHbond” tool was used to
predict potential hydrogen bonds between Leu317 and it’s surrounding amino
acids. This tool predicted that Leu317 forms a hydrogen bond with Ala313
(Figure 24B).
As with ADT2, a BLAST search was performed with the ADT5 sequence
and it was found that Ct-PDT had the highest similarity to the ADT5 sequence.
ADT5 was modeled against Ct-PDT and the position of Phe341 was identified
(Figure 25A). Similar to Leu317, Phe341 was predicted to be in the α-helix that
lies at the ACT domain interface and Phe ligand binding site in the Ct-PDT dimer.
A potential hydrogen bond between Phe341 and Ser337 was predicted with the
“FindHBond” tool (Figure 25B). Interestingly, Ser337 in ADT5 corresponds to the
same amino acid position as Ala313 in ADT2. So, both Leu317 in ADT2 and
Phe341 in ADT5 are predicted to form hydrogen bonds with the amino acids 4
positions towards their N-terminus. Then, the “Rotamers” tool was used to
substitute Phe341 to a Leu in the 3D homology modeled ADT5. This tool can
substitute an amino acid and will also predict the possible rotations in space in
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Figure 24. Leu317 and the 3D homology model for ADT2.
(A) 3D homology model for an ADT2 monomer. This model is based on the
structural information the monomer of the PDT protein from Chlorobium tepidum
(Ct-PDT) using the UCSF Chimera program. (B) Zoomed in view of the ADT2
ACT domain to highlight the position of Leu317 (green). The predicted hydrogen
bond between Leu317 and Ala313 (blue) is shown in orange.

	
  

102	
  
	
  

B'

A'

Ala313'

Leu317'

	
  

103	
  
	
  

Figure 25. Phe341 in the 3D homology modeled ADT5.
(A) ADT5 homology modeled monomer. The ADT5 sequence was homology
modeled against the monomer of the PDT homodimer from Chlorobium tepidium
(Ct-PDT) using UCSF Chimera’s “Modeller” program. (B) Zoomed view of
Phe341 (green), the amino acid required for PDT activity in ADT2. The predicted
hydrogen bond between Phe341 and Ser337 is shown in orange. (C) Zoomed
view of Leu341 (green), which was substituted for Phe341. The predicted
hydrogen bond between Leu341 and Ser337 is shown in orange.
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which the new amino acid might exist. The tool assigns a probability to each of
these different “rotamers”. Nine rotamers were identified for ADT5 and all of
these rotamers were predicted to form a hydrogen bond with the same Ser337.
The rotamer that was predicted with the greatest probability (75.3%) is shown in
Figure 25C. The “Clashes and Contacts” tool was used to predict if any of the
rotamers could physically interact with their surrounding amino acids, possibly
resulting in a displacement those surrounding amino acids or an overall
conformational change in the protein. However, no clashes or contacts were
identified for any of the nine rotamers (data not shown).
In summary, the predictions made by the UCSF Chimera program do not
indicate that the Phe341Leu substitution in ADT5 has any substantial effects on
interactions with amino acids in its nearby surroundings or the overall protein
conformation.

4 Discussion
The main goal of this study was to identify the amino acids that can
distinguish between ADTs and PDTs. To accomplish this, a family of six
Arabidopsis ADTs, two of which have PDT function (ADT1 and ADT2) and four of
which are only ADTs (ADT3 – ADT6) were studied. Three members of this
family, ADT2, ADT4 and ADT5 were chosen for analysis through domain
swapping and yeast complementation assays. Nineteen ADT chimeras were
generated through overlap extension PCR to consist of Arabidopsis sequences
from ADT2, which is a prephenate-accepting ADT, and ADT4 or ADT5, which are
solely arogenate-accepting ADTs. The chimeras were tested for PDT activity in a
pha2 PDT knockout yeast strain. I was able to identify that a Phe to Leu
substitution at amino acid position 341 in ADT5 can confer PDT function to this
arogenate-only ADT.
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4.1 Complementation results
S. cerevisiae is a useful organism in which to study protein function
because it can be grown as a haploid and therefore the allele it carries
determines its phenotype. If one allele is knocked out, the gene function is
eliminated in the yeast strain entirely. A mutant S. cerevisiae yeast strain named
pha2 was used for the complementation assay in this study. S. cerevisiae has a
single PDT coding sequence (PHA2), making it an ideal candidate for this assay.
When PHA2 is knocked out, the strain is unable to synthesize Phe and can only
survive if either an exogenous supply of Phe is provided or a gene with PDT
activity is transformed into and expressed in the yeast (Bross et al. 2011). Hence,
this provides a simple way to identify PDT activity in a strain that contains an
altered protein. Yeast growth indicates that the protein can complement the pha2
phenotype and therefore has PDT activity. Lack of yeast growth indicates that the
protein cannot complement the pha2 phenotype, and therefore does not have
PDT activity. This pha2 complementation assay has already been successfully
used to test the six Arabidopsis ADTs for PDT function (Bross et al. 2011). In this
study, ADT1 and ADT2 were able to complement the pha2 phenotype and ADT3
– ADT6 were not. Hence, ADT1 and ADT2 have PDT function and ADT3 – ADT6
do not.
ADT domain swapping chimeras were tested for PDT activity using the
pha2 complementation assay. The region that can confer PDT function to an
arogenate-only ADT was systematically narrowed down to a single amino acid
position. This amino acid was a Phe to Leu substitution at amino acid position
341 in ADT5, which conferred PDT activity to this enzyme. This position was
previously identified in an in silico approach (section 3.1) as a position which
could potentially distinguish between ADT and PDT function. It was first identified
in the Arabidopsis ADTs (green arrow in Figure 15), because it fulfilled three
requirements: that there was a conserved amino acid between ADT1 and ADT2
(Leu), that there was a conserved amino acid between ADT3 – ADT6 (Phe), and
that these two amino acids are different.
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Then, this position was located in the bacterial PDT sequences (green arrow in
Figure 14). Importantly, Leu was identified at this position in the PDTs, while Phe
was not. However, although Leu is present at this position in some of the
bacterial sequences, it is not highly conserved. In fact, it is only found in only 3 of
the 26 sequences in the alignment in Figure 14. In addition, several other amino
acids such as Trp, Thr, Asn Arg, and Lys are found at this position. Interestingly,
these amino acids have a wide range of different characteristics: Leu and Trp are
nonpolar and hydrophobic, Thr and Asn are polar and hydrophilic, and Arg and
Lys are positively charged. This indicates that Leu is not the only amino acid at
this position which can confer PDT function.
To check if the presence of a Leu at position 341 in ADT5 can be used to
predict PDT function in plant ADTs, the Arabidopsis ADT sequences were
compared to ADT sequences from P. hybrida. The P. hybrida ADT sequences
are the only other plant ADTs which have been biochemically analyzed (Maeda
et al. 2010). There are three enzymes in the P. hybrida ADT family, Ph-ADT1,
Ph-ADT2 and Ph-ADT3 (ACY79502.1, ACY79503.1, ACY79504.1, respectively)
all of which function predominantly as ADTs. However, Ph-ADT2 and Ph-ADT3
can also convert prephenate to phenylpyruvate (act as PDTs). An alignment of
the P. hybrida and the Arabidopsis ADT sequences is shown in Figure 26.
Interestingly, neither of the prephenate-accepting Ph-ADTs have a Leu at the
amino acid position corresponding to the Phe341Leu substitution that resulted in
PDT function in ADT5. In fact, Ph-ADT2 has a Met while Ph-ADT3 has an Ala.
This does not indicate that a Leu at this position can be used to predict PDT
function in plant ADTs. However, Ph-ADT1, which is solely arogenate-accepting,
has Phe at this location. This is the amino acid also found in the arogenatespecific Arabidopsis ADT3 – ADT6 at this position. This could indicate that a Phe
at this position might define ADT function, rather than a Leu at this position
defines PDT function. If this is the case, it is possible that many amino acids at
this position can allow for the acceptance of prephenate as a substrate but only a
Phe at this location eliminates prephenate recognition. Consistent with this
assumption, none of the bacterial PDT sequences that were
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Figure 26. Analysis of Leu317 from Arabidopsis and Petunia ADT
sequences.
Alignment of partial catalytic and ACT domain sequences from the six
Arabidopsis ADTs (At-ADT1 – At-ADT6) and the three Ph-ADT sequences from
Petunia hybrida (Ph-ADT1 – Ph-ADT3) generated with DNAMAN. At-ADT1, AtADT2, Ph-ADT2, and Ph-ADT3 are all predominantly arogenate-accepting but
also have a low level of prephenate recognition. All other enzymes in this
alignment are solely arogenate-accepting. Sequences from the N-terminal
catalytic domain are highlighted in blue and sequences from the C-terminal ACT
domain are highlighted in green. The position of Phe341Leu, the amino acid
substitution that conferred PDT function to ADT5, is highlighted in red. The amino
acid number at this position differs between the ADT enzymes because the
lengths of the transit peptides in these enzymes are highly variable. At this
position: the ADTs with PDT function have a Met (Ph-ADT2), an Asn (Ph-ADT3),
or a Leu (At-ADT1 and At-ADT2) whereas all of the solely arogenate-accepting
ADTs contain a Phe (Ph-ADT1 and At-ADT3 – At-ADT6).
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VLDDSADGFPKYFPYLFYVDFEASMADQRAQNALGHLKEFATFLRVLGSYPSDSGIAM............
YPMDMTPCCPSRDEK.......................................................
VVDGSNNGSAKYFDYLFYIDFEASMADTRAQHALGHLQEFASFIRILGCYPMDLVR..............
.....ASGGLKYFDYLFYVDFEASMADEVAQNALRHLEEFATFLRVLGSYPVDTTML.............
LVDEANVGTAKHFEYMFYIDFEASMAESRAQNALSEVQEFTSFLRVLGSYPMDMTSWSPSSSSSSSSTFS
VVGDGSFGTSKNFEYMFYVDFEASMAEPRAQNALAEVQEYTSFLRVLGSYPMDMTPWSMTSTEEA.....
VVGDENVGTSKHFEYTFYVDFEASMAEARAQNALAEVQEYTSFLRVLGSYPMDMTPWSTLPSEDV.....
VVDDANVGTAKHFEYMFYVDFEASMAEARAQNALAEVQEFTSFLRVLGSYPMDMTPWSPTSSTSS.....
IRLVDDANVGTAKHFEYMFYVDFEASMADVRAQNALAEVQEFTSFLRVLGSYPMDMTPWSPSRDA.....
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analyzed carried a Phe at the corresponding position in the bacterial alignment
(green arrow in Figure 14).
So, distinguishing between an ADT and a PDT based on this amino acid
position alone might be more complicated than originally anticipated. A Phe at
this position clearly allows for ADT function in ADT5, but future studies will need
to be completed to determine if this is a more general phenomena.
However, the results from the complementation analysis in this study
clearly show that a Phe to Leu substitution at amino acid position 341 can confer
PDT function to ADT5, an arogenate-specific ADT. Although this may be
surprising, there are many examples in the literature in which a single amino acid
change has altered the function of an entire protein. For example, a single amino
acid change in a cathepsin L protease that is secreted by the trematode Fasciola
hepatica altered this enzyme’s substrate specificity (Smooker et al. 2000). The
altered protein is able to cleave substrates with a proline at the cleavage site,
whereas the native protein cannot. In another example, a single amino acid
substitution in an aspartate aminotransferase from E. coli changed the pH
dependence of the enzyme (Jeffery et al. 2000). This change alters the kinetic
parameters of the enzyme, allowing the enzyme to recognize its aspartate
substrate at a different pH. In both of these examples, the amino acid substitution
responsible for the change in enzymatic activity is located outside of the catalytic
site. Importantly, both substitutions result in a change in the overall conformation
of the protein. This suggests that the overall protein conformation is more
important for function than the protein sequence. One could argue that PDT
enzymes themselves are an example of this hypothesis. For example, the PDT
enzymes from C. tepidum and S. aureus display very similar overall conformation
and function although their sequences are very distinct (only 27.3% identical
(Tan et al. 2008). Therefore, a substitution that does not affect the catalytic site
directly can substantially alter enzyme catalysis if it results in an overall
conformational change that transfers the effects of the substitution to the catalytic
site.
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4.2 The importance of the ACT domain
The Phe341Leu substitution that conferred PDT function to ADT5 is
located in the N-terminal region of the ACT domain. This was surprising since it
is more intuitive that the amino acid required for prephenate recognition would be
located in the catalytic domain, rather than the ACT domain. Characteristically,
ACT domains are ligand-binding domains that can be found in a diverse group of
metabolic enzymes that are regulated by allosteric binding of amino acids to this
domain (Grant 2006; Liberles et al. 2005). The effects of ligand binding to the
ACT domain are transferred to the catalytic site and can either inhibit or activate
enzymatic activity (Grant 2006).
The enzymatic activity of the bacterial PDTs is allosterically inhibited by
Phe binding to the ACT domain. The site of Phe binding in PDTs is in the Nterminal region of the ACT domain, and the amino acids that form the
hydrophobic Phe-binding pocket are highly conserved among these enzymes
(Tan et al. 2008). The two most highly conserved amino acid motifs in this region
are the GALV and ESRP motifs, which are essential to Phe binding and feedback
inhibition (Pohnert et al. 1999). These amino acids contribute directly to
interactions with the Phe ligand as well as the formation of the closed ACT
domain conformation. These amino acids correspond to G209SLF and E229SRP
in Ct-PDT (Figure 27A).
The GALV and ESRP motifs are also very highly conserved within the plant
ADTs (Tan et al. 2008). These amino acids correspond to G297PGVL and
E319SRP in Arabidopsis ADT2 (Figure 27B) and G328TSVL and E350SRP in
ADT5 (Figure 27C) and are essential for Phe binding. In fact, a substitution of
S320A in Arabidopsis ADT2 substantially decreased Phe-induced feedback
inhibition of enzymatic function and increased the free Phe levels 160-fold
(Huang et al. 2010). An S298I substitution in the ESRP motif in an Oryza sativa
ADT also decreased Phe-induced inhibition of this enzyme (Yamada et al. 2008).
This indicates that these motifs are required for Phe binding in plant ADTs, and
that changes in this area of the ACT domain can indirectly affect the catalytic site
in these enzymes as well. Although the Phe341Leu substitution in ADT5 is not
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part of the GALV or ESRP motif it is located right in between them (Figure 27B).
Therefore, it is understandable that this amino acid change could also indirectly
affect substrate recognition.
Due to a lack of structural information, the mechanism of allosteric Phe
inhibition in the plant ADTs is unknown. However, this mechanism has been
determined in two bacterial PDTs (Tan et al. 2008). Crystal structures of the
PDTs from C. tepidum and S. aureus indicate that Phe binding in the ACT
domain results in an overall conformational change in these proteins, reducing
the access of prephenate to the catalytic cleft in the catalytic domain.
These PDT enzymes form homodimers in which the two catalytic domains
and the two ACT domains are closely aligned (Figure 4; Tan et al. 2008). An
extended catalytic cleft, which hosts the active site, forms between the two
catalytic domains. Interestingly, the N-termini of several α-helices from both
monomers point into this cleft, making it highly positive (about 3.0 positive
charges; (Hol 1985). This attracts prephenate, which is negatively charged, to the
active site. When Phe is not bound to the ACT domain the dimer exists in an
open conformation in which prephenate can access the catalytic cleft. However,
when two Phe molecules simultaneously bind to two hydrophobic pockets at the
ACT dimer interface, the ACT domains shift closer together. This movement is
transferred throughout the entire protein, resulting in an overall change in
conformation that splits the catalytic cleft and reduces the access of prephenate
to the active site. Figure 5 shows a schematic of this conformational change.
During this change, several of the positively charged α-helix N-termini that point
into the cleft are rotated, decreasing the attractive positive charge near the active
site. Therefore, it has been conclusively shown that amino acids in the region of
the Ct-PDT and Sa-PDT ACT domain that correspond to the region of the
Phe341Leu substitution in ADT5 can cause an overall change in protein
conformation and indirectly affect the ability of prephenate to bind at the active
site.
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Figure 27. GALV and ESRP motifs in Ct-PDT, ADT2 and ADT5.
The amino acid site corresponding to Leu317 in ADT2 is in close proximity to
highly conserved GALV and ESRP motifs in the Ct-PDT protein and the ADT2
and ADT5 homology models. (A) The GALV and ESRP motif in the Ct-PDT
dimer, which correspond to G209SLF and E229SRP in each monomer,
respectively. The motifs from monomer A (blue) are shown in light blue and the
motifs from monomer B (red) are shown in pink. Leu220 from each monomer is
indicated in green. (B) The GALV and ESRP motifs (P298GVL and E319SRP,
respectively) and Leu317 in the ADT2 homology model. The motifs are shown in
blue, and Leu317 is shown in green. (C) The GALV and ESRP motifs
(G328TSVL and E350SRP, respectively) and Phe341, the amino acid that
corresponds to Leu317 in ADT2, in the ADT5 homology model. The motifs are
shown in pink, and Phe341 is shown in green.
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Although there is no structural information available for the plant ADTs, the
protein conformation of these enzymes can be predicted with a 3D homology
modeling computer program such as UCSF Chimera. This program can model a
protein sequence with unknown structure against a known protein structural
template. Using the PDT from C. tepidum as a template, the overall conformation
of Arabidopsis ADT2 and ADT5 was predicted in order to determine whether the
Phe341Leu substitution in ADT5 has an impact on its surrounding amino acids or
the ADT5 overall protein conformation (section 3.8). The predictions made by the
UCSF Chimera program did not indicate that the Phe341Leu substitution in
ADT5 has any substantial effects on interactions with its nearby amino acids or
the overall protein conformation. However, since these interactions are predicted
based on data from the PDT protein, they may not accurately reflect the actual
ADT amino acid interactions or protein conformation in vivo. In addition, since the
program can only model a single chain or subunit at one time, only interactions
within an ADT monomer could be predicted.
Dimerization is required for both catalytic function and Phe feedback
inhibition in the bacterial PDTs (Tan et al. 2008). Interestingly, it has been shown
that all six of the Arabidopsis ADTs can form homo and heterodimers in planta
(Styranko 2011). However, whether or not this dimerization is required for ADT
catalytic function or Phe inhibition in the ADTs is currently unknown. Therefore,
we cannot yet predict whether the Phe341Leu substitution in the ACT domain of
ADT5 results in an overall change in protein dimer conformation similar to the
change described for the bacterial PDTs (Tan et al. 2008).

4.3 Future directions
Using a pha2 yeast complementation assay, it was identified that the
Phe341Leu substitution in ADT5 introduced PDT function to this enzyme. To
ensure that this substitution can confer PDT function to the other solely
arogenate-accepting ADTs, future research should substitute this amino acid
position in ADT3, ADT4 and ADT6 as well. As well, the Phe at this position in the
other arogenate-only ADTs could be substituted to one of the other amino acids
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found at this position in the bacterial PDTs (Trp, Thr, Asn Arg), to determine if
this confers PDT function. In addition, since the in silico analysis indicated it may
be the lack of the Phe at this position that confers PDT function as opposed to a
presence of Leu specifically, Leu317 should be substituted for Phe in ADT2. If a
Phe at this position is in fact responsible for removing PDT function, it is
expected that the Leu317Phe substituted ADT2 would lose PDT function and
therefore not be able to complement the pha2 phenotype.
However, the pha2 complementation analysis can only determine if a
protein has PDT activity, it cannot be used to test whether the altered ADT
proteins have retained or lost their ADT activity. Therefore, it is important that all
of the altered proteins are tested through biochemical analysis to determine
whether these proteins can still recognize arogenate as a substrate.
The lack of structural information available for the plant ADTs greatly
hinders our ability to understand substrate recognition and Phe inhibition in these
proteins. Future research should concentrate on determining crystal structures
for both the unaltered ADT proteins as well as those containing the ACT domain
substitution that alter substrate recognition. This structural information will reveal
whether the catalytic and allosteric inhibition mechanisms described for the
bacterial PDTs (Tan et al. 2008) are similar in the Arabidopsis ADTs.

4.4 Conclusions
This study represents the first characterization of an amino acid that can
potentially distinguish between ADT and PDT function. Through the generation of
domain swapping ADT chimeras and a series of pha2 yeast complementation
assays, I have identified that Phe341Leu, a single amino acid substitution in the
ACT domain of ADT5, results in PDT function to this arogenate-only ADT. This
study is an example of the ability of a single amino acid outside of the catalytic
site to substantially impact enzymatic activity. These results also emphasize the
importance of the ACT domain and the need to understand its role in indirectly
affecting substrate recognition and protein function. As Phe is a building block of
protein synthesis and a precursor to a wide variety of important secondary
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metabolites in plants, understanding the enzymes involved in its biosynthesis
pathway is important to regulating and manipulating the synthesis of this
essential amino acid.
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6 Appendices
Appendix A.
The number of mutants that must be generated and screened in order to
exhaustively search a randomly mutated library can be calculated with the
following equation:
# mutants = bk x n!/(n-k)!
“b” represents the number of different bases the wild type nucleotide could be
changed to. “b” will always equal 3, because one of the four nucleotides
(A,T,G,C) must be substituted to a different nucleotide to result in a mutation. “k”
represents the number of nucleotide mutations that must be introduced in order
to alter gene function and “n” represents the length of the sequence to be
mutated (in nucleotides).
For example, in order to introduce 4 nucleotide mutations to a sequence that is
10 nucleotides in length through random mutagenesis:
# mutants = 34 x 10!/(10-4)!
# mutants = 408240
408240 mutants would need to be generated and screened. For a full-length ADT
gene of approximately 1200 bp, this number is essentially infinite. Therefore, it
was deemed that random mutagenesis is not a practical method for determining
the sequences required for PDT function in the prephenate-accepting
Arabidopsis ADTs.
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“Converting the substrate specificity of arogenate dehydratases (ADTs) in Arabidopsis thaliana.”
• Supervisor: Dr. Susanne Kohalmi , GPA: 4.0 (2012-2014)

Bachelor of Science – Honors Specialization in Genetics

2008 – 2012
UNIVERSITY OF WESTERN ONTARIO – London, ON
• Dean’s Honors List (2009-2012), GPA: 3.7 (2010-2012)
• Received the highest grade in Genes & Genomes (Bio4562b), an advanced fourth year genetics course.

Awards and Honors
• Offered: Western University’s Science Entrance
Scholarship (in the event of transfer to the Doctoral
program) (2014)
• Western University’s Biology Graduate Travel
Award (2014)
• The Canadian Society of Plant Biologist’s George
H. Duff Award (2014)
• Western University’s Global Opportunities Award
(2014)

• Western University’s Western Science Graduate
Entrance Scholarship (2012)
• The University of Toronto’s Scholarship for
Dependents of Faculty Members (2008-2012)
• Western University’s Entrance Scholarship for High
Academic Achievement (2008)

Research Presentations
Poster Presenter
07/14
CANADIAN & AMERICAN SOCIETY OF PLANT BIOLOGISTS ANNUAL MEETING – Portland, OR
• “Converting the substrate specificity of arogenate dehydratases (ADTs) from Arabidopsis thaliana.” Megan
Smith-Uffen & Susanne E. Kohalmi (2014).

Oral Presenter
12/13
CANADIAN SOCIETY OF PLANT BIOLOGISTS EASTERN REGIONAL CONFERENCE – Mississauga, ON
• “Dissecting substrate specificity of arogenate dehydratases (ADTs) from Arabidopsis thaliana.” Megan
Smith-Uffen & Susanne E. Kohalmi (2013).

Poster Presenter
06/13
CANADIAN SOCIETY OF PLANT BIOLOGISTS ANNUAL NATIONAL CONFERENCE – Quebec City, QC

• “Identifying the amino acids responsible for substrate specificity in arogenate dehydratases (ADTs) through
the generation of gene chimeras.”

	
  

